NO318083B1 - Pyrrolsubstituert 2-indolinon protein kinase inhibitorer - Google Patents

Pyrrolsubstituert 2-indolinon protein kinase inhibitorer Download PDF

Info

Publication number: NO318083B1
Authority: NO; Norway
Prior art keywords: dimethyl; pyrrol; dihydroindol; oxindole; oxo
Prior art date: 1998-05-29

Application number

NO20005916A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005916D0 (no

NO20005916L (no

Inventor

Peng Cho Tang

Gerald Mcmahon

Li Sun

Original Assignee

Sugen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-29

Filing date

2000-11-22

Publication date

2005-01-31

2000-11-22 Application filed by Sugen Inc filed Critical Sugen Inc

2000-11-22 Publication of NO20005916D0 publication Critical patent/NO20005916D0/no

2001-01-29 Publication of NO20005916L publication Critical patent/NO20005916L/no

2005-01-31 Publication of NO318083B1 publication Critical patent/NO318083B1/no

Links

-1 Pyrrole-substituted 2-indolinone Chemical class 0.000 title claims description 47
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 232
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 53
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 42
102000001253 Protein Kinase Human genes 0.000 claims description 33
108060006633 protein kinase Proteins 0.000 claims description 33
102000005962 receptors Human genes 0.000 claims description 32
108020003175 receptors Proteins 0.000 claims description 32
238000011282 treatment Methods 0.000 claims description 30
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 28
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 27
229910052739 hydrogen Inorganic materials 0.000 claims description 25
239000001257 hydrogen Substances 0.000 claims description 24
230000033115 angiogenesis Effects 0.000 claims description 22
229940079593 drug Drugs 0.000 claims description 21
239000000126 substance Substances 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 14
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
206010006187 Breast cancer Diseases 0.000 claims description 11
208000026310 Breast neoplasm Diseases 0.000 claims description 11
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 11
206010012601 diabetes mellitus Diseases 0.000 claims description 11
208000020816 lung neoplasm Diseases 0.000 claims description 11
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 10
201000005202 lung cancer Diseases 0.000 claims description 10
206010033128 Ovarian cancer Diseases 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
208000005017 glioblastoma Diseases 0.000 claims description 9
NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims description 8
206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
201000004681 Psoriasis Diseases 0.000 claims description 8
230000003463 hyperproliferative effect Effects 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
206010005003 Bladder cancer Diseases 0.000 claims description 7
206010009944 Colon cancer Diseases 0.000 claims description 7
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
201000005112 urinary bladder cancer Diseases 0.000 claims description 7
208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
230000001900 immune effect Effects 0.000 claims description 6
230000004968 inflammatory condition Effects 0.000 claims description 6
201000001441 melanoma Diseases 0.000 claims description 6
206010016654 Fibrosis Diseases 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 5
230000004761 fibrosis Effects 0.000 claims description 5
201000010536 head and neck cancer Diseases 0.000 claims description 5
208000014829 head and neck neoplasm Diseases 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
208000037803 restenosis Diseases 0.000 claims description 5
206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
TWMZFPSODZCNLQ-UHFFFAOYSA-N 3-[5-[(5-iodo-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC(I)=CC=C3NC2=O)=C1C TWMZFPSODZCNLQ-UHFFFAOYSA-N 0.000 claims description 4
206010003571 Astrocytoma Diseases 0.000 claims description 4
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
206010018338 Glioma Diseases 0.000 claims description 4
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
230000002526 effect on cardiovascular system Effects 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
201000008482 osteoarthritis Diseases 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
JWFUKWLQYWSUOU-UHFFFAOYSA-N 3-[2,4-dimethyl-5-[(6-morpholin-4-yl-2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC=C(C=C3NC2=O)N2CCOCC2)=C1C JWFUKWLQYWSUOU-UHFFFAOYSA-N 0.000 claims description 3
LUOFXVYSCYRHFS-UHFFFAOYSA-N 3-[[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrol-2-yl]methylidene]-6-(3-methoxyphenyl)-1h-indol-2-one Chemical compound COC1=CC=CC(C=2C=C3NC(=O)C(=CC4=C(C(CCCN5CCOCC5)=C(C)N4)C)C3=CC=2)=C1 LUOFXVYSCYRHFS-UHFFFAOYSA-N 0.000 claims description 3
KXDDHRYCUUEICK-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-6-(2-methoxyphenyl)-1h-indol-2-one Chemical compound COC1=CC=CC=C1C1=CC=C(C(=CC2=C(C(CCCN(C)C)=C(C)N2)C)C(=O)N2)C2=C1 KXDDHRYCUUEICK-UHFFFAOYSA-N 0.000 claims description 3
HGJHMUJDVHGDFS-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-6-methoxy-1h-indol-2-one Chemical compound O=C1NC2=CC(OC)=CC=C2C1=CC=1NC(C)=C(CCCN(C)C)C=1C HGJHMUJDVHGDFS-UHFFFAOYSA-N 0.000 claims description 3
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
208000032612 Glial tumor Diseases 0.000 claims description 3
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
108091008046 non-receptor tyrosine kinases Proteins 0.000 claims description 3
102000037979 non-receptor tyrosine kinases Human genes 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
YEVBDKUJUCJAMN-UHFFFAOYSA-N 3-[5-[(6-hydroxy-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC=C(O)C=C3NC2=O)=C1C YEVBDKUJUCJAMN-UHFFFAOYSA-N 0.000 claims description 2
XLHWOGDAUMWGHR-UHFFFAOYSA-N 3-[5-[[6-(3-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound COC1=CC=CC(C=2C=C3NC(=O)C(=CC4=C(C(CCC(O)=O)=C(C)N4)C)C3=CC=2)=C1 XLHWOGDAUMWGHR-UHFFFAOYSA-N 0.000 claims description 2
BCRNCFOBRHFGBC-UHFFFAOYSA-N 3-[[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrol-2-yl]methylidene]-6-(4-methoxyphenyl)-1h-indol-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC2=C(C(CCCN3CCOCC3)=C(C)N2)C)C(=O)N2)C2=C1 BCRNCFOBRHFGBC-UHFFFAOYSA-N 0.000 claims description 2
VRSDIXKBDMNAJU-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indole-5-sulfonamide Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(=CC=C3NC2=O)S(N)(=O)=O)=C1C VRSDIXKBDMNAJU-UHFFFAOYSA-N 0.000 claims description 2
VIRGIOQJECYOKB-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-4-(2-hydroxyethyl)-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=C(CCO)C=CC=C3NC2=O)=C1C VIRGIOQJECYOKB-UHFFFAOYSA-N 0.000 claims description 2
LSYZZVKELDHCDH-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-n,n-dimethyl-2-oxo-1h-indole-5-sulfonamide Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(=CC=C3NC2=O)S(=O)(=O)N(C)C)=C1C LSYZZVKELDHCDH-UHFFFAOYSA-N 0.000 claims description 2
208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
230000001363 autoimmune Effects 0.000 claims description 2
125000002757 morpholinyl group Chemical group 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 3
APYYTEJNOZQZNA-UHFFFAOYSA-N 3-[2,4-dimethyl-5-[(2-oxo-6-phenyl-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC=C(C=C3NC2=O)C=2C=CC=CC=2)=C1C APYYTEJNOZQZNA-UHFFFAOYSA-N 0.000 claims 1
CUQJCVAMGWHJPW-UHFFFAOYSA-N 3-[5-[(5-chloro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC(Cl)=CC=C3NC2=O)=C1C CUQJCVAMGWHJPW-UHFFFAOYSA-N 0.000 claims 1
MPBRWFJYTOVGPY-UHFFFAOYSA-N 3-[5-[[6-(2-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound COC1=CC=CC=C1C1=CC=C(C(=CC2=C(C(CCC(O)=O)=C(C)N2)C)C(=O)N2)C2=C1 MPBRWFJYTOVGPY-UHFFFAOYSA-N 0.000 claims 1
KFUOUFXHFQOQAG-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-2-oxo-n-propan-2-yl-1h-indole-5-sulfonamide Chemical compound C12=CC(S(=O)(=O)NC(C)C)=CC=C2NC(=O)C1=CC=1NC(C)=C(CCCN(C)C)C=1C KFUOUFXHFQOQAG-UHFFFAOYSA-N 0.000 claims 1
PPTVYGAPIZYPBT-UHFFFAOYSA-N 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(Br)=CC=C3NC2=O)=C1C PPTVYGAPIZYPBT-UHFFFAOYSA-N 0.000 claims 1
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 333
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 288
239000007787 solid Substances 0.000 description 226
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 217
239000000203 mixture Substances 0.000 description 210
229910001868 water Inorganic materials 0.000 description 187
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 166
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 166
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 109
239000002244 precipitate Substances 0.000 description 106
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 103
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 101
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 98
210000004027 cell Anatomy 0.000 description 97
239000011541 reaction mixture Substances 0.000 description 94
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 82
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
239000000243 solution Substances 0.000 description 79
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
238000000034 method Methods 0.000 description 68
201000010099 disease Diseases 0.000 description 67
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
238000003828 vacuum filtration Methods 0.000 description 63
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 61
229920002554 vinyl polymer Polymers 0.000 description 56
230000000694 effects Effects 0.000 description 50
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 47
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 47
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 46
239000012267 brine Substances 0.000 description 46
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
206010028980 Neoplasm Diseases 0.000 description 45
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
102000027426 receptor tyrosine kinases Human genes 0.000 description 43
108091008598 receptor tyrosine kinases Proteins 0.000 description 43
239000000741 silica gel Substances 0.000 description 43
229910002027 silica gel Inorganic materials 0.000 description 43
239000000706 filtrate Substances 0.000 description 42
229960000583 acetic acid Drugs 0.000 description 38
201000011510 cancer Diseases 0.000 description 31
230000003197 catalytic effect Effects 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 31
239000003921 oil Substances 0.000 description 31
235000019198 oils Nutrition 0.000 description 31
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 30
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 28
239000000047 product Substances 0.000 description 27
238000001914 filtration Methods 0.000 description 26
150000003839 salts Chemical class 0.000 description 26
239000000725 suspension Substances 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 24
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 24
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
238000002965 ELISA Methods 0.000 description 23
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 23
239000012043 crude product Substances 0.000 description 23
WEMKCIPNUIQYSM-UHFFFAOYSA-N 3-(5-formyl-4-methyl-1h-pyrrol-3-yl)propanoic acid Chemical compound CC=1C(CCC(O)=O)=CNC=1C=O WEMKCIPNUIQYSM-UHFFFAOYSA-N 0.000 description 22
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
239000010410 layer Substances 0.000 description 22
RUILENPFHDHTRC-UHFFFAOYSA-N 3-(5-formyl-2,4-dimethyl-1h-pyrrol-3-yl)propanoic acid Chemical compound CC=1NC(C=O)=C(C)C=1CCC(O)=O RUILENPFHDHTRC-UHFFFAOYSA-N 0.000 description 21
230000019491 signal transduction Effects 0.000 description 21
238000005160 1H NMR spectroscopy Methods 0.000 description 20
238000007792 addition Methods 0.000 description 20
239000005457 ice water Substances 0.000 description 20
230000008859 change Effects 0.000 description 19
239000000284 extract Substances 0.000 description 19
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 19
238000003756 stirring Methods 0.000 description 19
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
239000012044 organic layer Substances 0.000 description 18
229940002612 prodrug Drugs 0.000 description 18
239000000651 prodrug Substances 0.000 description 18
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
230000001413 cellular effect Effects 0.000 description 16
239000008194 pharmaceutical composition Substances 0.000 description 16
238000010992 reflux Methods 0.000 description 16
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 15
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 15
BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 15
239000003446 ligand Substances 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
239000012312 sodium hydride Substances 0.000 description 15
229910000104 sodium hydride Inorganic materials 0.000 description 15
238000004809 thin layer chromatography Methods 0.000 description 15
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 14
238000003556 assay Methods 0.000 description 14
150000005623 oxindoles Chemical class 0.000 description 14
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
238000012360 testing method Methods 0.000 description 14
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 14
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 13
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 13
108091000080 Phosphotransferase Proteins 0.000 description 13
150000001299 aldehydes Chemical class 0.000 description 13
230000004663 cell proliferation Effects 0.000 description 13
239000000463 material Substances 0.000 description 13
239000002609 medium Substances 0.000 description 13
102000020233 phosphotransferase Human genes 0.000 description 13
UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 12
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
230000003993 interaction Effects 0.000 description 12
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
229910000029 sodium carbonate Inorganic materials 0.000 description 12
239000002904 solvent Substances 0.000 description 12
230000004862 vasculogenesis Effects 0.000 description 12
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 11
230000002159 abnormal effect Effects 0.000 description 11
238000009472 formulation Methods 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
230000002062 proliferating effect Effects 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
DFGZEOUBIHLXFD-UHFFFAOYSA-N 5-methoxy-1,3-dihydroindol-2-one Chemical class COC1=CC=C2NC(=O)CC2=C1 DFGZEOUBIHLXFD-UHFFFAOYSA-N 0.000 description 10
JARRYVQFBQVOBE-UHFFFAOYSA-N 6-bromo-1,3-dihydroindol-2-one Chemical class BrC1=CC=C2CC(=O)NC2=C1 JARRYVQFBQVOBE-UHFFFAOYSA-N 0.000 description 10
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 10
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000000654 additive Substances 0.000 description 10
125000003118 aryl group Chemical group 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
239000011550 stock solution Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
LLLKBUWXODIMEW-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)CC2=C1 LLLKBUWXODIMEW-UHFFFAOYSA-N 0.000 description 9
USRZZPHRQZGXFH-UHFFFAOYSA-N 4-methyl-1,3-dihydroindol-2-one Chemical compound CC1=CC=CC2=C1CC(=O)N2 USRZZPHRQZGXFH-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
102000009465 Growth Factor Receptors Human genes 0.000 description 9
108010009202 Growth Factor Receptors Proteins 0.000 description 9
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
239000002585 base Substances 0.000 description 9
230000024245 cell differentiation Effects 0.000 description 9
230000010261 cell growth Effects 0.000 description 9
230000001086 cytosolic effect Effects 0.000 description 9
239000012362 glacial acetic acid Substances 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
230000026731 phosphorylation Effects 0.000 description 9
235000019260 propionic acid Nutrition 0.000 description 9
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 9
239000000758 substrate Substances 0.000 description 9
FYBNVKMJOOYPGI-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-5-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2NC(=O)CC2=C1 FYBNVKMJOOYPGI-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
101710098940 Pro-epidermal growth factor Proteins 0.000 description 8
102100033237 Pro-epidermal growth factor Human genes 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
239000006180 TBST buffer Substances 0.000 description 8
150000001413 amino acids Chemical group 0.000 description 8
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000000969 carrier Substances 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
230000003834 intracellular effect Effects 0.000 description 8
239000007788 liquid Substances 0.000 description 8
238000010907 mechanical stirring Methods 0.000 description 8
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
239000002243 precursor Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
238000012546 transfer Methods 0.000 description 8
VIMNAEVMZXIKFL-UHFFFAOYSA-N 5-bromo-1,3-dihydroindol-2-one Chemical class BrC1=CC=C2NC(=O)CC2=C1 VIMNAEVMZXIKFL-UHFFFAOYSA-N 0.000 description 7
FAIHEVFTQPMOLE-UHFFFAOYSA-N 5-iodo-1,3-dihydroindol-2-one Chemical compound IC1=CC=C2NC(=O)CC2=C1 FAIHEVFTQPMOLE-UHFFFAOYSA-N 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
108010031794 IGF Type 1 Receptor Proteins 0.000 description 7
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
238000013459 approach Methods 0.000 description 7
229910002092 carbon dioxide Inorganic materials 0.000 description 7
229910002091 carbon monoxide Inorganic materials 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000010898 silica gel chromatography Methods 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
FAPIBOYLMCVQRF-UHFFFAOYSA-N 1-fluoro-4-(2-methoxyphenyl)-2-nitrobenzene Chemical group COC1=CC=CC=C1C1=CC=C(F)C([N+]([O-])=O)=C1 FAPIBOYLMCVQRF-UHFFFAOYSA-N 0.000 description 6
WXJWBEAGVWVEDM-UHFFFAOYSA-N 5-(2-chloroacetyl)-1,3-dihydroindol-2-one Chemical compound ClCC(=O)C1=CC=C2NC(=O)CC2=C1 WXJWBEAGVWVEDM-UHFFFAOYSA-N 0.000 description 6
WWJLCYHYLZZXBE-UHFFFAOYSA-N 5-chloro-1,3-dihydroindol-2-one Chemical class ClC1=CC=C2NC(=O)CC2=C1 WWJLCYHYLZZXBE-UHFFFAOYSA-N 0.000 description 6
HXQDSHSATAEREW-UHFFFAOYSA-N 5-methyl-1,3-dihydroindol-2-one Chemical compound CC1=CC=C2NC(=O)CC2=C1 HXQDSHSATAEREW-UHFFFAOYSA-N 0.000 description 6
OXOQGUGIJKUSRP-UHFFFAOYSA-N 6-methoxy-1,3-dihydroindol-2-one Chemical class COC1=CC=C2CC(=O)NC2=C1 OXOQGUGIJKUSRP-UHFFFAOYSA-N 0.000 description 6
BRTXRFCARXOWJV-UHFFFAOYSA-N 6-phenyl-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC=C1C1=CC=CC=C1 BRTXRFCARXOWJV-UHFFFAOYSA-N 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 6
102000003746 Insulin Receptor Human genes 0.000 description 6
108010001127 Insulin Receptor Proteins 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 6
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 6
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 6
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
UOIFTOBIGNZZSO-UHFFFAOYSA-N acetic acid;ethyl acetate;hexane Chemical compound CC(O)=O.CCCCCC.CCOC(C)=O UOIFTOBIGNZZSO-UHFFFAOYSA-N 0.000 description 6
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000003054 catalyst Substances 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
239000007789 gas Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
235000003642 hunger Nutrition 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
230000037361 pathway Effects 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
230000011664 signaling Effects 0.000 description 6
230000037351 starvation Effects 0.000 description 6
235000002374 tyrosine Nutrition 0.000 description 6
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
HPXJIGZLXHQSGU-UHFFFAOYSA-N 5-(2-chloroethyl)-1,3-dihydroindol-2-one Chemical compound ClCCC1=CC=C2NC(=O)CC2=C1 HPXJIGZLXHQSGU-UHFFFAOYSA-N 0.000 description 5
HRMQSJQDTTZJPC-UHFFFAOYSA-N 5-acetyl-1,3-dihydroindol-2-one Chemical compound CC(=O)C1=CC=C2NC(=O)CC2=C1 HRMQSJQDTTZJPC-UHFFFAOYSA-N 0.000 description 5
CRPVKCLICXWDGA-UHFFFAOYSA-N 5-chloro-4-methyl-1,3-dihydroindol-2-one Chemical compound C1=C(Cl)C(C)=C2CC(=O)NC2=C1 CRPVKCLICXWDGA-UHFFFAOYSA-N 0.000 description 5
YCIHQDVIAISDPS-UHFFFAOYSA-N 5-formyl-2,4-dimethyl-1h-pyrrole-3-carboxylic acid Chemical compound CC=1NC(C=O)=C(C)C=1C(O)=O YCIHQDVIAISDPS-UHFFFAOYSA-N 0.000 description 5
OPHFPDJTRBPFFC-UHFFFAOYSA-N 6-(2-methoxyphenyl)-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC=C1C1=CC=C(CC(=O)N2)C2=C1 OPHFPDJTRBPFFC-UHFFFAOYSA-N 0.000 description 5
IUPFDSDZXMXHJK-UHFFFAOYSA-N 6-(3-ethoxyphenyl)-1,3-dihydroindol-2-one Chemical compound CCOC1=CC=CC(C=2C=C3NC(=O)CC3=CC=2)=C1 IUPFDSDZXMXHJK-UHFFFAOYSA-N 0.000 description 5
IRQBUMYFAYXEGV-UHFFFAOYSA-N 6-(3-methoxyphenyl)-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(C=2C=C3NC(=O)CC3=CC=2)=C1 IRQBUMYFAYXEGV-UHFFFAOYSA-N 0.000 description 5
OCOCBVKMMMIDLI-UHFFFAOYSA-N 6-amino-1,3-dihydroindol-2-one Chemical compound NC1=CC=C2CC(=O)NC2=C1 OCOCBVKMMMIDLI-UHFFFAOYSA-N 0.000 description 5
PKQNTFAOZIVXCE-UHFFFAOYSA-N 6-fluoro-1,3-dihydroindol-2-one Chemical class FC1=CC=C2CC(=O)NC2=C1 PKQNTFAOZIVXCE-UHFFFAOYSA-N 0.000 description 5
206010039491 Sarcoma Diseases 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
208000019425 cirrhosis of liver Diseases 0.000 description 5
229940127089 cytotoxic agent Drugs 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
239000002198 insoluble material Substances 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
210000003584 mesangial cell Anatomy 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
208000008443 pancreatic carcinoma Diseases 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
239000007858 starting material Substances 0.000 description 5
235000000346 sugar Nutrition 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
PBPINVZBVWMQCT-UHFFFAOYSA-N 2-(2-nitro-4-phenylphenyl)acetic acid Chemical compound C1=C([N+]([O-])=O)C(CC(=O)O)=CC=C1C1=CC=CC=C1 PBPINVZBVWMQCT-UHFFFAOYSA-N 0.000 description 4
LBZPHZBNFDOCCR-UHFFFAOYSA-N 2-(4-bromo-2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Br)C=C1[N+]([O-])=O LBZPHZBNFDOCCR-UHFFFAOYSA-N 0.000 description 4
CLOUBWLUOFJGML-UHFFFAOYSA-N 2-(5-amino-2-methoxyphenyl)acetohydrazide Chemical compound COC1=CC=C(N)C=C1CC(=O)NN CLOUBWLUOFJGML-UHFFFAOYSA-N 0.000 description 4
VMUNVLRBZWDDHR-UHFFFAOYSA-N 2-[4-(4-methoxyphenyl)-2-nitrophenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(CC(O)=O)C([N+]([O-])=O)=C1 VMUNVLRBZWDDHR-UHFFFAOYSA-N 0.000 description 4
PJRWVQFEVVSTKZ-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C2NC(=O)CC2=C1 PJRWVQFEVVSTKZ-UHFFFAOYSA-N 0.000 description 4
BAAJNXQYDCMIFO-UHFFFAOYSA-N 3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrole-2-carbaldehyde Chemical compound N1C(C=O)=C(C)C(CCCN2CCOCC2)=C1C BAAJNXQYDCMIFO-UHFFFAOYSA-N 0.000 description 4
JVCREVCBOGOWCL-UHFFFAOYSA-N 3-pyrrolidin-1-yl-1,3-dihydroindol-2-one Chemical class O=C1NC2=CC=CC=C2C1N1CCCC1 JVCREVCBOGOWCL-UHFFFAOYSA-N 0.000 description 4
XWDKOXPQYRNLOO-UHFFFAOYSA-N 4-(3-ethoxyphenyl)-1-fluoro-2-nitrobenzene Chemical group CCOC1=CC=CC(C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 XWDKOXPQYRNLOO-UHFFFAOYSA-N 0.000 description 4
PFZOPWMHTMNDMV-UHFFFAOYSA-N 5-ethyl-1,3-dihydroindol-2-one Chemical compound CCC1=CC=C2NC(=O)CC2=C1 PFZOPWMHTMNDMV-UHFFFAOYSA-N 0.000 description 4
MYUNWQZTMMYCCB-UHFFFAOYSA-N 6-(4-methoxyphenyl)-1,3-dihydroindol-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(CC(=O)N2)C2=C1 MYUNWQZTMMYCCB-UHFFFAOYSA-N 0.000 description 4
ZOJZYAPVVOLQQB-UHFFFAOYSA-N 6-hydroxy-1,3-dihydroindol-2-one Chemical compound OC1=CC=C2CC(=O)NC2=C1 ZOJZYAPVVOLQQB-UHFFFAOYSA-N 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
241000283707 Capra Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102100039137 Insulin receptor-related protein Human genes 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 4
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 4
241000220317 Rosa Species 0.000 description 4
230000004913 activation Effects 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
150000001340 alkali metals Chemical class 0.000 description 4
230000003305 autocrine Effects 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
235000011089 carbon dioxide Nutrition 0.000 description 4
230000032823 cell division Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000000576 coating method Methods 0.000 description 4
FSADKQTZVABRCO-UHFFFAOYSA-N dimethyl 2-(2-nitro-4-phenylphenyl)propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=CC=C1 FSADKQTZVABRCO-UHFFFAOYSA-N 0.000 description 4
NJAONFWUEGWOPG-UHFFFAOYSA-N dimethyl 2-(4-bromo-2-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C(Br)C=C1[N+]([O-])=O NJAONFWUEGWOPG-UHFFFAOYSA-N 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000013265 extended release Methods 0.000 description 4
239000004744 fabric Substances 0.000 description 4
230000003176 fibrotic effect Effects 0.000 description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
230000006870 function Effects 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
230000012010 growth Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
108010054372 insulin receptor-related receptor Proteins 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
239000002502 liposome Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
XFOSBARPNHJHHD-UHFFFAOYSA-N n-methyl-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C2NC(=O)CC2=C1 XFOSBARPNHJHHD-UHFFFAOYSA-N 0.000 description 4
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 3
FCHZACFMGHJGEE-UHFFFAOYSA-N 1-fluoro-2-nitro-4-phenylbenzene Chemical group C1=C(F)C([N+](=O)[O-])=CC(C=2C=CC=CC=2)=C1 FCHZACFMGHJGEE-UHFFFAOYSA-N 0.000 description 3
OWVXRMWQDIKWMO-UHFFFAOYSA-N 2-[4-(3-ethoxyphenyl)-2-nitrophenyl]acetic acid Chemical compound CCOC1=CC=CC(C=2C=C(C(CC(O)=O)=CC=2)[N+]([O-])=O)=C1 OWVXRMWQDIKWMO-UHFFFAOYSA-N 0.000 description 3
MDEHFNBKDPLEEJ-UHFFFAOYSA-N 2-hydroxyimino-n-(4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(NC(=O)C=NO)C=C1 MDEHFNBKDPLEEJ-UHFFFAOYSA-N 0.000 description 3
SAGABBLUUSFKNW-UHFFFAOYSA-N 3-(2,4-dimethyl-1h-pyrrol-3-yl)propanoic acid Chemical compound CC1=CNC(C)=C1CCC(O)=O SAGABBLUUSFKNW-UHFFFAOYSA-N 0.000 description 3
SOFWMZAVOINJGR-UHFFFAOYSA-N 3-(2-oxo-1,3-dihydroindol-5-yl)propanenitrile Chemical compound N#CCCC1=CC=C2NC(=O)CC2=C1 SOFWMZAVOINJGR-UHFFFAOYSA-N 0.000 description 3
LDNTUJJLQVCEQX-UHFFFAOYSA-N 4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrole-2-carbaldehyde Chemical compound CN(C)CCCC1=C(C)NC(C=O)=C1C LDNTUJJLQVCEQX-UHFFFAOYSA-N 0.000 description 3
BKTIIWWGWJQMPF-UHFFFAOYSA-N 5,7-dibromo-4-methyl-1,3-dihydroindol-2-one Chemical compound C1=C(Br)C(C)=C2CC(=O)NC2=C1Br BKTIIWWGWJQMPF-UHFFFAOYSA-N 0.000 description 3
JPUYXUBUJJDJNL-UHFFFAOYSA-N 5-amino-1,3-dihydroindol-2-one Chemical compound NC1=CC=C2NC(=O)CC2=C1 JPUYXUBUJJDJNL-UHFFFAOYSA-N 0.000 description 3
WSOSXQWLCFAZGI-UHFFFAOYSA-N 5-bromo-4-methyl-1,3-dihydroindol-2-one Chemical compound C1=C(Br)C(C)=C2CC(=O)NC2=C1 WSOSXQWLCFAZGI-UHFFFAOYSA-N 0.000 description 3
FUZSPEICNULOGO-UHFFFAOYSA-N 5-ethoxycarbonyl-3-(3-ethoxy-3-oxopropyl)-4-methyl-1h-pyrrole-2-carboxylic acid Chemical compound CCOC(=O)CCC=1C(C)=C(C(=O)OCC)NC=1C(O)=O FUZSPEICNULOGO-UHFFFAOYSA-N 0.000 description 3
DDIIYGHHUMKDGI-UHFFFAOYSA-N 5-fluoro-1,3-dihydroindol-2-one Chemical class FC1=CC=C2NC(=O)CC2=C1 DDIIYGHHUMKDGI-UHFFFAOYSA-N 0.000 description 3
LZPKWQOLOCLSBO-UHFFFAOYSA-N 6-(trifluoromethyl)-1,3-dihydroindol-2-one Chemical class FC(F)(F)C1=CC=C2CC(=O)NC2=C1 LZPKWQOLOCLSBO-UHFFFAOYSA-N 0.000 description 3
CENVPIZOTHULGJ-UHFFFAOYSA-N 6-chloro-1,3-dihydroindol-2-one Chemical class ClC1=CC=C2CC(=O)NC2=C1 CENVPIZOTHULGJ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
206010012689 Diabetic retinopathy Diseases 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
102000052575 Proto-Oncogene Human genes 0.000 description 3
108700020978 Proto-Oncogene Proteins 0.000 description 3
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 3
101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 3
102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 3
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 3
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 3
208000005718 Stomach Neoplasms Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
YGMYINIHIYQFHB-UHFFFAOYSA-N dimethyl 2-(4-fluoro-2-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C(F)C=C1[N+]([O-])=O YGMYINIHIYQFHB-UHFFFAOYSA-N 0.000 description 3
YSGMYMHSGKXDPG-UHFFFAOYSA-N dimethyl 2-[4-(2-methoxyphenyl)-2-nitrophenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=CC=C1OC YSGMYMHSGKXDPG-UHFFFAOYSA-N 0.000 description 3
ZGSOIPAJGLECGE-UHFFFAOYSA-N dimethyl 2-[4-(3-ethoxyphenyl)-2-nitrophenyl]propanedioate Chemical compound CCOC1=CC=CC(C=2C=C(C(C(C(=O)OC)C(=O)OC)=CC=2)[N+]([O-])=O)=C1 ZGSOIPAJGLECGE-UHFFFAOYSA-N 0.000 description 3
NIXVEKYSWIWAGT-UHFFFAOYSA-N dimethyl 2-[4-(4-methoxyphenyl)-2-nitrophenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=C(OC)C=C1 NIXVEKYSWIWAGT-UHFFFAOYSA-N 0.000 description 3
235000021186 dishes Nutrition 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
238000011534 incubation Methods 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
238000002372 labelling Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
CYBPPDZFRDSSME-UHFFFAOYSA-N methyl 2-oxo-1,3-dihydroindole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(=O)CC2=C1 CYBPPDZFRDSSME-UHFFFAOYSA-N 0.000 description 3
KKCOXRJQIIYHCQ-UHFFFAOYSA-N methyl 4-[(2-oxo-1,3-dihydroindol-5-yl)carbamoyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)NC1=CC=C(NC(=O)C2)C2=C1 KKCOXRJQIIYHCQ-UHFFFAOYSA-N 0.000 description 3
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 3
239000013642 negative control Substances 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000003586 protic polar solvent Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
125000000168 pyrrolyl group Chemical group 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
201000011549 stomach cancer Diseases 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
CHCWUTJYLUBETR-UHFFFAOYSA-N (3-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=CC(B(O)O)=C1 CHCWUTJYLUBETR-UHFFFAOYSA-N 0.000 description 2
NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
YUZGGDGIGDSVPA-UHFFFAOYSA-N 1,3,5-trimethyl-4-(3-morpholin-4-yl-3-oxopropyl)pyrrole-2-carbaldehyde Chemical compound CN1C(C=O)=C(C)C(CCC(=O)N2CCOCC2)=C1C YUZGGDGIGDSVPA-UHFFFAOYSA-N 0.000 description 2
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
UOXZPEGXZWCOPR-UHFFFAOYSA-N 1-fluoro-4-(3-methoxyphenyl)-2-nitrobenzene Chemical group COC1=CC=CC(C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 UOXZPEGXZWCOPR-UHFFFAOYSA-N 0.000 description 2
MXFZNWJJUITGAC-UHFFFAOYSA-N 1-fluoro-4-(4-methoxyphenyl)-2-nitrobenzene Chemical group C1=CC(OC)=CC=C1C1=CC=C(F)C([N+]([O-])=O)=C1 MXFZNWJJUITGAC-UHFFFAOYSA-N 0.000 description 2
ROGHUJUFCRFUSO-UHFFFAOYSA-N 1h-indole-4-carboxylic acid Chemical class OC(=O)C1=CC=CC2=C1C=CN2 ROGHUJUFCRFUSO-UHFFFAOYSA-N 0.000 description 2
WFKNETIJXXWRHO-UHFFFAOYSA-N 2-(2-methyl-6-nitrophenyl)acetic acid Chemical compound CC1=CC=CC([N+]([O-])=O)=C1CC(O)=O WFKNETIJXXWRHO-UHFFFAOYSA-N 0.000 description 2
LAFOTQFKZXKMFD-UHFFFAOYSA-N 2-(4-fluoro-2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1[N+]([O-])=O LAFOTQFKZXKMFD-UHFFFAOYSA-N 0.000 description 2
JBRBLYXXQZRQOQ-UHFFFAOYSA-N 2-[2-nitro-4-[3-[(2,2,2-trifluoroacetyl)amino]phenyl]phenyl]acetic acid Chemical compound C1=C([N+]([O-])=O)C(CC(=O)O)=CC=C1C1=CC=CC(NC(=O)C(F)(F)F)=C1 JBRBLYXXQZRQOQ-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
SOEWWIDREFDEJC-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)-2-nitrophenyl]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=C(CC(O)=O)C([N+]([O-])=O)=C1 SOEWWIDREFDEJC-UHFFFAOYSA-N 0.000 description 2
MWTVRSIFCMGCDS-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)-3-nitrophenyl]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=C(CC(O)=O)C=C1[N+]([O-])=O MWTVRSIFCMGCDS-UHFFFAOYSA-N 0.000 description 2
UHFXANYMAIRBOF-UHFFFAOYSA-N 2-[4-(3-methoxyphenyl)-2-nitrophenyl]acetic acid Chemical compound COC1=CC=CC(C=2C=C(C(CC(O)=O)=CC=2)[N+]([O-])=O)=C1 UHFXANYMAIRBOF-UHFFFAOYSA-N 0.000 description 2
IKEMNOMJHMIJNL-UHFFFAOYSA-N 2-[4-(3-methoxyphenyl)-3-nitrophenyl]acetic acid Chemical compound COC1=CC=CC(C=2C(=CC(CC(O)=O)=CC=2)[N+]([O-])=O)=C1 IKEMNOMJHMIJNL-UHFFFAOYSA-N 0.000 description 2
ALXJUSWINGKGAW-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1CC(=O)N2 ALXJUSWINGKGAW-UHFFFAOYSA-N 0.000 description 2
AEJCJSGFTXNMLX-UHFFFAOYSA-N 2-oxo-n-[4-(trifluoromethyl)phenyl]-1,3-dihydroindole-5-sulfonamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NS(=O)(=O)C1=CC=C(NC(=O)C2)C2=C1 AEJCJSGFTXNMLX-UHFFFAOYSA-N 0.000 description 2
ZDZVVSVVBTXHJX-UHFFFAOYSA-N 2-oxo-n-propan-2-yl-1,3-dihydroindole-5-sulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=C2NC(=O)CC2=C1 ZDZVVSVVBTXHJX-UHFFFAOYSA-N 0.000 description 2
BKVSCRLYGVMHFD-UHFFFAOYSA-N 3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1h-pyrrole-2-carbaldehyde Chemical compound C1CN(C)CCN1C(=O)C1=C(C)NC(C=O)=C1C BKVSCRLYGVMHFD-UHFFFAOYSA-N 0.000 description 2
QSGALCFLGKPSHR-UHFFFAOYSA-N 3-(2,4-dimethyl-1h-pyrrol-3-yl)-1-morpholin-4-ylpropan-1-one Chemical compound CC1=CNC(C)=C1CCC(=O)N1CCOCC1 QSGALCFLGKPSHR-UHFFFAOYSA-N 0.000 description 2
XANKLCNGFQBQPL-UHFFFAOYSA-N 3-(2-oxo-1,3-dihydroindol-4-yl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC2=C1CC(=O)N2 XANKLCNGFQBQPL-UHFFFAOYSA-N 0.000 description 2
NEBLVPRYSZZNEF-UHFFFAOYSA-N 3-(2-oxo-1,3-dihydroindol-5-yl)propanoic acid Chemical compound OC(=O)CCC1=CC=C2NC(=O)CC2=C1 NEBLVPRYSZZNEF-UHFFFAOYSA-N 0.000 description 2
NQWCWPNNZSFZGL-UHFFFAOYSA-N 3-(4-fluoro-3-nitrophenyl)aniline Chemical compound NC1=CC=CC(C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 NQWCWPNNZSFZGL-UHFFFAOYSA-N 0.000 description 2
FYMPIGRRSUORAR-UHFFFAOYSA-N 3-(4-methyl-1h-pyrrol-3-yl)propanoic acid Chemical compound CC1=CNC=C1CCC(O)=O FYMPIGRRSUORAR-UHFFFAOYSA-N 0.000 description 2
OMJBYYJQTBHLOG-UHFFFAOYSA-N 3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)-n-(2-morpholin-4-ylethyl)propanamide Chemical compound CN1C(C=O)=C(C)C(CCC(=O)NCCN2CCOCC2)=C1C OMJBYYJQTBHLOG-UHFFFAOYSA-N 0.000 description 2
YYDKBZZXKDZMAR-UHFFFAOYSA-N 3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)-n-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1NC(=O)CCC1=C(C)N(C)C(C=O)=C1C YYDKBZZXKDZMAR-UHFFFAOYSA-N 0.000 description 2
HPOXJAOEPQODRF-UHFFFAOYSA-N 3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)-n-phenylpropanamide Chemical compound CN1C(C=O)=C(C)C(CCC(=O)NC=2C=CC=CC=2)=C1C HPOXJAOEPQODRF-UHFFFAOYSA-N 0.000 description 2
PQTLMRNITSYCAL-UHFFFAOYSA-N 3-[1-(cyclohexylmethyl)-5-formyl-2,4-dimethylpyrrol-3-yl]propanoic acid Chemical compound O=CC1=C(C)C(CCC(O)=O)=C(C)N1CC1CCCCC1 PQTLMRNITSYCAL-UHFFFAOYSA-N 0.000 description 2
ACGXXKQLAPXTBG-UHFFFAOYSA-N 3-[5-[(6-hydroxy-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC=C(O)C=C3NC2=O)=C1C ACGXXKQLAPXTBG-UHFFFAOYSA-N 0.000 description 2
MAUJBIMARUNWBM-UHFFFAOYSA-N 3-[5-[[6-(3-ethoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound CCOC1=CC=CC(C=2C=C3NC(=O)C(=CC4=C(C(CCC(O)=O)=C(C)N4)C)C3=CC=2)=C1 MAUJBIMARUNWBM-UHFFFAOYSA-N 0.000 description 2
GNDPWHKLEXPOKK-UHFFFAOYSA-N 3-[5-formyl-1-(2-methoxy-2-oxoethyl)-2,4-dimethylpyrrol-3-yl]propanoic acid Chemical compound COC(=O)CN1C(C)=C(CCC(O)=O)C(C)=C1C=O GNDPWHKLEXPOKK-UHFFFAOYSA-N 0.000 description 2
QXZLRPVSNYQHNF-UHFFFAOYSA-N 3-[5-formyl-1-[(3-methoxyphenyl)methyl]-2,4-dimethylpyrrol-3-yl]propanoic acid Chemical compound COC1=CC=CC(CN2C(=C(C)C(CCC(O)=O)=C2C)C=O)=C1 QXZLRPVSNYQHNF-UHFFFAOYSA-N 0.000 description 2
UMHJYAYUHPOHQO-UHFFFAOYSA-N 3-[[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrol-2-yl]methylidene]-1h-indol-2-one Chemical compound CC=1NC(C=C2C3=CC=CC=C3NC2=O)=C(C)C=1CCCN1CCOCC1 UMHJYAYUHPOHQO-UHFFFAOYSA-N 0.000 description 2
CPZVUWMFRDBPCS-UHFFFAOYSA-N 4-butyl-1,3-dihydroindol-2-one Chemical compound CCCCC1=CC=CC2=C1CC(=O)N2 CPZVUWMFRDBPCS-UHFFFAOYSA-N 0.000 description 2
SLEITZPBBNQRTC-UHFFFAOYSA-N 5-bromo-3-[[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrol-2-yl]methylidene]-1h-indol-2-one Chemical compound CC=1NC(C=C2C3=CC(Br)=CC=C3NC2=O)=C(C)C=1CCCN1CCOCC1 SLEITZPBBNQRTC-UHFFFAOYSA-N 0.000 description 2
DYTNNGQPYKZMNF-UHFFFAOYSA-N 5-ethoxy-1,3-dihydroindol-2-one Chemical compound CCOC1=CC=C2NC(=O)CC2=C1 DYTNNGQPYKZMNF-UHFFFAOYSA-N 0.000 description 2
ZGTUSQAQXWSMDW-UHFFFAOYSA-N 5-hydroxy-1,3-dihydroindol-2-one Chemical class OC1=CC=C2NC(=O)CC2=C1 ZGTUSQAQXWSMDW-UHFFFAOYSA-N 0.000 description 2
VAJCSPZKMVQIAP-UHFFFAOYSA-N 5-methyl-1h-indole-2,3-dione Chemical compound CC1=CC=C2NC(=O)C(=O)C2=C1 VAJCSPZKMVQIAP-UHFFFAOYSA-N 0.000 description 2
SESKLCQTEFAMPM-UHFFFAOYSA-N 5-morpholin-4-ylsulfonyl-1,3-dihydroindol-2-one Chemical compound C=1C=C2NC(=O)CC2=CC=1S(=O)(=O)N1CCOCC1 SESKLCQTEFAMPM-UHFFFAOYSA-N 0.000 description 2
JQCGHRDKVZPCRO-UHFFFAOYSA-N 5-nitro-1,3-dihydroindol-2-one Chemical compound [O-][N+](=O)C1=CC=C2NC(=O)CC2=C1 JQCGHRDKVZPCRO-UHFFFAOYSA-N 0.000 description 2
ULFMXQCBEHNLMZ-UHFFFAOYSA-N 7-bromo-5-chloro-1,3-dihydroindol-2-one Chemical compound BrC1=CC(Cl)=CC2=C1NC(=O)C2 ULFMXQCBEHNLMZ-UHFFFAOYSA-N 0.000 description 2
VMUIOEOYZHJLEZ-UHFFFAOYSA-N 7-fluoro-1,3-dihydroindol-2-one Chemical class FC1=CC=CC2=C1NC(=O)C2 VMUIOEOYZHJLEZ-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108091008606 PDGF receptors Proteins 0.000 description 2
241000609499 Palicourea Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
102000014400 SH2 domains Human genes 0.000 description 2
108050003452 SH2 domains Proteins 0.000 description 2
108060006706 SRC Proteins 0.000 description 2
102000001332 SRC Human genes 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229960004424 carbon dioxide Drugs 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
108700010039 chimeric receptor Proteins 0.000 description 2
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
229960002327 chloral hydrate Drugs 0.000 description 2
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000013058 crude material Substances 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940075894 denatured ethanol Drugs 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
125000000950 dibromo group Chemical group Br* 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
UIRNQCRCSAYHKC-UHFFFAOYSA-N dimethyl 2-(2-methoxycarbonyl-6-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=C(C(=O)OC)C=CC=C1[N+]([O-])=O UIRNQCRCSAYHKC-UHFFFAOYSA-N 0.000 description 2
FTMKVOQBYTWJFN-UHFFFAOYSA-N dimethyl 2-[2-nitro-4-[3-[(2,2,2-trifluoroacetyl)amino]phenyl]phenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=CC(NC(=O)C(F)(F)F)=C1 FTMKVOQBYTWJFN-UHFFFAOYSA-N 0.000 description 2
KEGXRXDQFPQJPZ-UHFFFAOYSA-N dimethyl 2-[4-(3-methoxyphenyl)-2-nitrophenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=CC(OC)=C1 KEGXRXDQFPQJPZ-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
230000032692 embryo implantation Effects 0.000 description 2
MLUBCFKZELZSHV-UHFFFAOYSA-N ethyl 5-methyl-4,6-dioxoheptanoate Chemical compound CCOC(=O)CCC(=O)C(C)C(C)=O MLUBCFKZELZSHV-UHFFFAOYSA-N 0.000 description 2
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000031146 intracellular signal transduction Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
WFQOIJIXNFOYCM-UHFFFAOYSA-N methyl 2-[2-nitro-4-(trifluoromethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O WFQOIJIXNFOYCM-UHFFFAOYSA-N 0.000 description 2
JBCQPBVZKBEHNF-UHFFFAOYSA-N methyl 2-chloro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1Cl JBCQPBVZKBEHNF-UHFFFAOYSA-N 0.000 description 2
UZAFMJPJIDIXTG-UHFFFAOYSA-N methyl 3-[1-(2,2-dimethylpropyl)-5-formyl-2,4-dimethylpyrrol-3-yl]propanoate Chemical compound COC(=O)CCC=1C(C)=C(C=O)N(CC(C)(C)C)C=1C UZAFMJPJIDIXTG-UHFFFAOYSA-N 0.000 description 2
RQMGRMCOFPLXIY-UHFFFAOYSA-N methyl 3-[1-(cyclohexylmethyl)-5-formyl-2,4-dimethylpyrrol-3-yl]propanoate Chemical compound CC1=C(CCC(=O)OC)C(C)=C(C=O)N1CC1CCCCC1 RQMGRMCOFPLXIY-UHFFFAOYSA-N 0.000 description 2
FIJRVYHHOYXJSG-UHFFFAOYSA-N methyl 3-[1-[(4-fluorophenyl)methyl]-5-formyl-2,4-dimethylpyrrol-3-yl]propanoate Chemical compound CC1=C(CCC(=O)OC)C(C)=C(C=O)N1CC1=CC=C(F)C=C1 FIJRVYHHOYXJSG-UHFFFAOYSA-N 0.000 description 2
TXEFZVUGRUTDQT-UHFFFAOYSA-N methyl 3-[5-formyl-1-[(3-methoxyphenyl)methyl]-2,4-dimethylpyrrol-3-yl]propanoate Chemical compound CC1=C(CCC(=O)OC)C(C)=C(C=O)N1CC1=CC=CC(OC)=C1 TXEFZVUGRUTDQT-UHFFFAOYSA-N 0.000 description 2
MSYGVTQVRNLPMW-UHFFFAOYSA-N n,n-dimethyl-2-oxo-3h-indole-1-sulfonamide Chemical compound C1=CC=C2N(S(=O)(=O)N(C)C)C(=O)CC2=C1 MSYGVTQVRNLPMW-UHFFFAOYSA-N 0.000 description 2
UQRSFMWYCLZIMU-UHFFFAOYSA-N n-(2-oxo-1,3-dihydroindol-6-yl)benzamide Chemical compound C=1C=C2CC(=O)NC2=CC=1NC(=O)C1=CC=CC=C1 UQRSFMWYCLZIMU-UHFFFAOYSA-N 0.000 description 2
HWRRRQBVCDXNKB-UHFFFAOYSA-N n-(2-oxo-1,3-dihydroindol-6-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C2CC(=O)NC2=C1 HWRRRQBVCDXNKB-UHFFFAOYSA-N 0.000 description 2
UZVVIMFOBRKSOV-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-formyl-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CN(C)CCNC(=O)C1=C(C)NC(C=O)=C1C UZVVIMFOBRKSOV-UHFFFAOYSA-N 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000033667 organ regeneration Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000011505 plaster Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
125000001453 quaternary ammonium group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000010802 sludge Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
229940048086 sodium pyrophosphate Drugs 0.000 description 2
239000012265 solid product Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
ALOFLJUGJDMERX-UHFFFAOYSA-N tert-butyl 2-hydroxyimino-3-oxobutanoate Chemical compound CC(=O)C(=NO)C(=O)OC(C)(C)C ALOFLJUGJDMERX-UHFFFAOYSA-N 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000006163 transport media Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
238000005406 washing Methods 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
YVCYOVLYYZRNJC-UHFFFAOYSA-N (2-methoxyphenoxy)boronic acid Chemical compound COC1=CC=CC=C1OB(O)O YVCYOVLYYZRNJC-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
OGUSQFGGNLZTKG-BCLLBKCYSA-N (2s)-2,5-diamino-5-oxopentanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OGUSQFGGNLZTKG-BCLLBKCYSA-N 0.000 description 1
PBQQBKGLQWKLKQ-QPEQYQDCSA-N (3z)-3-[[4-(2-carboxyethyl)-3-methyl-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indole-5-carboxylic acid Chemical compound OC(=O)CCC1=CNC(\C=C/2C3=CC(=CC=C3NC\2=O)C(O)=O)=C1C PBQQBKGLQWKLKQ-QPEQYQDCSA-N 0.000 description 1
OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
FVHAWXWFPBPFOS-UHFFFAOYSA-N 1,2-dimethyl-3-nitrobenzene Chemical group CC1=CC=CC([N+]([O-])=O)=C1C FVHAWXWFPBPFOS-UHFFFAOYSA-N 0.000 description 1
JQOBFOUVKCTYEP-UHFFFAOYSA-N 1,3,5-trimethyl-4-(3-oxo-3-piperidin-1-ylpropyl)pyrrole-2-carbaldehyde Chemical compound CN1C(C=O)=C(C)C(CCC(=O)N2CCCCC2)=C1C JQOBFOUVKCTYEP-UHFFFAOYSA-N 0.000 description 1
XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 1
CCAWDIFJOBKBSE-UHFFFAOYSA-N 1-(chloromethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1 CCAWDIFJOBKBSE-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VFERJFHPHSUIHY-UHFFFAOYSA-N 1-methyl-2-nitro-4-(trifluoromethyl)benzene Chemical compound CC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O VFERJFHPHSUIHY-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
QHIGJGOWDRZLHX-UHFFFAOYSA-N 2,2,2-trifluoro-n-[3-(4-fluoro-3-nitrophenyl)phenyl]acetamide Chemical compound C1=C(F)C([N+](=O)[O-])=CC(C=2C=C(NC(=O)C(F)(F)F)C=CC=2)=C1 QHIGJGOWDRZLHX-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
KCNISYPADDTFDO-UHFFFAOYSA-N 2,4-dinitrophenylacetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O KCNISYPADDTFDO-UHFFFAOYSA-N 0.000 description 1
RHELIKWEKJQBMB-UHFFFAOYSA-N 2-[4-(2-methoxyphenyl)-2-nitrophenyl]propanedioic acid Chemical compound COC1=CC=CC=C1C1=CC=C(C(C(O)=O)C(O)=O)C([N+]([O-])=O)=C1 RHELIKWEKJQBMB-UHFFFAOYSA-N 0.000 description 1
ZVMRVJMSSDJXJD-UHFFFAOYSA-N 2-[4-(3-methoxyphenyl)-2-nitrophenyl]propanedioic acid Chemical compound COC1=CC=CC(C=2C=C(C(C(C(O)=O)C(O)=O)=CC=2)[N+]([O-])=O)=C1 ZVMRVJMSSDJXJD-UHFFFAOYSA-N 0.000 description 1
AVHSJBXMJCAJIT-UHFFFAOYSA-N 2-[4-(4-methoxyphenyl)-2-nitrophenyl]propanedioic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(C(O)=O)C(O)=O)C([N+]([O-])=O)=C1 AVHSJBXMJCAJIT-UHFFFAOYSA-N 0.000 description 1
PJBFHGHMMOGYNF-UHFFFAOYSA-N 2-amino-3-ethoxy-3-oxopropanoic acid;hydrochloride Chemical compound Cl.CCOC(=O)C(N)C(O)=O PJBFHGHMMOGYNF-UHFFFAOYSA-N 0.000 description 1
UQKYXSFVOIMJCD-UHFFFAOYSA-N 2-fluoro-1-nitro-3-phenylbenzene Chemical group [O-][N+](=O)C1=CC=CC(C=2C=CC=CC=2)=C1F UQKYXSFVOIMJCD-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
PFCMHOLHFDZWRN-UHFFFAOYSA-N 2-oxo-n-phenyl-1,3-dihydroindole-5-sulfonamide Chemical class C=1C=C2NC(=O)CC2=CC=1S(=O)(=O)NC1=CC=CC=C1 PFCMHOLHFDZWRN-UHFFFAOYSA-N 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
JHDQERQROBFSSO-UHFFFAOYSA-N 3,3-dibromo-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CC=C2C(Br)(Br)C(=O)NC2=N1 JHDQERQROBFSSO-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
ORHYERPPJXHNIJ-UHFFFAOYSA-N 3-(1-benzyl-5-formyl-2,4-dimethylpyrrol-3-yl)propanoic acid Chemical compound O=CC1=C(C)C(CCC(O)=O)=C(C)N1CC1=CC=CC=C1 ORHYERPPJXHNIJ-UHFFFAOYSA-N 0.000 description 1
RYCSNJCJOVQGBC-UHFFFAOYSA-N 3-(1-cyclopropyl-2h-pyridin-4-yl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C(C=C1)=CCN1C1CC1 RYCSNJCJOVQGBC-UHFFFAOYSA-N 0.000 description 1
PAGJUJSCMPSQRY-UHFFFAOYSA-N 3-(4-ethyl-5-formyl-1h-pyrrol-3-yl)propanoic acid Chemical compound CCC=1C(CCC(O)=O)=CNC=1C=O PAGJUJSCMPSQRY-UHFFFAOYSA-N 0.000 description 1
VGVPFRRWNPRXJX-UHFFFAOYSA-N 3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)-n-[4-(trifluoromethyl)phenyl]propanamide Chemical compound CN1C(C=O)=C(C)C(CCC(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VGVPFRRWNPRXJX-UHFFFAOYSA-N 0.000 description 1
DAWSVCYPGVSKSH-UHFFFAOYSA-N 3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)propanoic acid Chemical compound CC=1C(CCC(O)=O)=C(C)N(C)C=1C=O DAWSVCYPGVSKSH-UHFFFAOYSA-N 0.000 description 1
VFLYEFSTBSBGAY-UHFFFAOYSA-N 3-[1-[(3-fluorophenyl)methyl]-5-formyl-2,4-dimethylpyrrol-3-yl]propanoic acid Chemical compound O=CC1=C(C)C(CCC(O)=O)=C(C)N1CC1=CC=CC(F)=C1 VFLYEFSTBSBGAY-UHFFFAOYSA-N 0.000 description 1
HTJNLVJFTCEGCR-UHFFFAOYSA-N 3-[2,4-dimethyl-5-[(4-methyl-2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=C(C)C=CC=C3NC2=O)=C1C HTJNLVJFTCEGCR-UHFFFAOYSA-N 0.000 description 1
WLRWNSHJNWQJBI-UHFFFAOYSA-N 3-[2,4-dimethyl-5-[(5-methyl-2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC(C)=CC=C3NC2=O)=C1C WLRWNSHJNWQJBI-UHFFFAOYSA-N 0.000 description 1
CUYCEBZNBCKUCD-UHFFFAOYSA-N 3-[3-[[4-(2-carboxyethyl)-3-methyl-1h-pyrrol-2-yl]methylidene]-2-oxo-1h-indol-5-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC(CCC(O)=O)=CC=C3NC2=O)=C1C CUYCEBZNBCKUCD-UHFFFAOYSA-N 0.000 description 1
YLOCIDYFMMJTMC-UHFFFAOYSA-N 3-[4-methyl-5-[(2-oxo-5-sulfamoyl-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC(=CC=C3NC2=O)S(N)(=O)=O)=C1C YLOCIDYFMMJTMC-UHFFFAOYSA-N 0.000 description 1
CEFJMJRPRONXNH-UNOMPAQXSA-N 3-[4-methyl-5-[(z)-(2-oxo-6-phenyl-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(\C=C/2C3=CC=C(C=C3NC\2=O)C=2C=CC=CC=2)=C1C CEFJMJRPRONXNH-UNOMPAQXSA-N 0.000 description 1
WNNYWBXPUXYLGT-UHFFFAOYSA-N 3-[5-[(5,6-dimethoxy-2-oxo-1H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid 3-(5-formyl-4-methyl-1H-pyrrol-3-yl)propanoic acid Chemical compound C(=O)(O)CCC=1C(=C(NC1)C=O)C.COC=1C=C2C(C(NC2=CC1OC)=O)=CC1=C(C(=CN1)CCC(=O)O)C WNNYWBXPUXYLGT-UHFFFAOYSA-N 0.000 description 1
CQXPYMNBBOWLME-UHFFFAOYSA-N 3-[5-[(5-bromo-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=CC(Br)=CC=C3NC2=O)=C1C CQXPYMNBBOWLME-UHFFFAOYSA-N 0.000 description 1
IJTQZRFOGIWTCI-UHFFFAOYSA-N 3-[5-[(5-bromo-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC(Br)=CC=C3NC2=O)=C1C IJTQZRFOGIWTCI-UHFFFAOYSA-N 0.000 description 1
KJTYTLSMFCQANO-UHFFFAOYSA-N 3-[5-[(5-chloro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]propanoic acid 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoic acid Chemical compound C(=O)(O)CCC1=C(NC(=C1C)C=O)C.ClC=1C=C2C(C(NC2=CC1)=O)=CC1=C(C(=C(N1)C)CCC(=O)O)C KJTYTLSMFCQANO-UHFFFAOYSA-N 0.000 description 1
SQISXLYGNHYPKD-UHFFFAOYSA-N 3-[5-[(5-chloro-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC(Cl)=CC=C3NC2=O)=C1C SQISXLYGNHYPKD-UHFFFAOYSA-N 0.000 description 1
IIWYUYODLPITHL-UHFFFAOYSA-N 3-[5-[(5-chloro-4-methyl-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(C=C2C3=C(C)C(Cl)=CC=C3NC2=O)=C1C IIWYUYODLPITHL-UHFFFAOYSA-N 0.000 description 1
LZCUBQASVPMVEA-UHFFFAOYSA-N 3-[5-[(5-chloro-4-methyl-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=C(C)C(Cl)=CC=C3NC2=O)=C1C LZCUBQASVPMVEA-UHFFFAOYSA-N 0.000 description 1
ZNOWLXVEKYCWBE-UHFFFAOYSA-N 3-[5-[(5-iodo-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC(I)=CC=C3NC2=O)=C1C ZNOWLXVEKYCWBE-UHFFFAOYSA-N 0.000 description 1
PUFZOSHTFRHZGE-UHFFFAOYSA-N 3-[5-[(5-methoxy-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound C12=CC(OC)=CC=C2NC(=O)C1=CC=1NC=C(CCC(O)=O)C=1C PUFZOSHTFRHZGE-UHFFFAOYSA-N 0.000 description 1
GGPNSZWDDIDANF-UHFFFAOYSA-N 3-[5-[(6-bromo-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=CNC(C=C2C3=CC=C(Br)C=C3NC2=O)=C1C GGPNSZWDDIDANF-UHFFFAOYSA-N 0.000 description 1
FTYXAWPLQFJPBB-ZSOIEALJSA-N 3-[5-[(z)-(6-methoxy-2-oxo-1h-indol-3-ylidene)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound O=C1NC2=CC(OC)=CC=C2\C1=C\C=1NC=C(CCC(O)=O)C=1C FTYXAWPLQFJPBB-ZSOIEALJSA-N 0.000 description 1
IZKQKZYHPAYOKJ-UNOMPAQXSA-N 3-[5-[(z)-[6-(2-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound COC1=CC=CC=C1C1=CC=C(\C(=C\C2=C(C(CCC(O)=O)=CN2)C)C(=O)N2)C2=C1 IZKQKZYHPAYOKJ-UNOMPAQXSA-N 0.000 description 1
YAHVZVQVATYZMK-NDENLUEZSA-N 3-[5-[(z)-[6-(3-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound COC1=CC=CC(C=2C=C3NC(=O)C(=C\C4=C(C(CCC(O)=O)=CN4)C)/C3=CC=2)=C1 YAHVZVQVATYZMK-NDENLUEZSA-N 0.000 description 1
RDIYTLWMJLEVPM-NDENLUEZSA-N 3-[5-[(z)-[6-(4-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(\C(=C\C2=C(C(CCC(O)=O)=CN2)C)C(=O)N2)C2=C1 RDIYTLWMJLEVPM-NDENLUEZSA-N 0.000 description 1
JAKZLBJBNMIQMP-UHFFFAOYSA-N 3-[5-[[6-(4-methoxyphenyl)-2-oxo-1h-indol-3-ylidene]methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC2=C(C(CCC(O)=O)=C(C)N2)C)C(=O)N2)C2=C1 JAKZLBJBNMIQMP-UHFFFAOYSA-N 0.000 description 1
UHKITYTXCXBLNM-UHFFFAOYSA-N 3-[[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1h-pyrrol-2-yl]methylidene]-6-phenyl-1h-indol-2-one Chemical compound CC=1C(CCCN2CCOCC2)=C(C)NC=1C=C(C1=CC=2)C(=O)NC1=CC=2C1=CC=CC=C1 UHKITYTXCXBLNM-UHFFFAOYSA-N 0.000 description 1
VWZUQMYAXGZACH-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methyl]-6-(3-methoxyphenyl)-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(C=2C=C3NC(=O)C(CC4=C(C(CCCN(C)C)=C(C)N4)C)C3=CC=2)=C1 VWZUQMYAXGZACH-UHFFFAOYSA-N 0.000 description 1
RTHKPDGJBJRDHW-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC=CC=C3NC2=O)=C1C RTHKPDGJBJRDHW-UHFFFAOYSA-N 0.000 description 1
MUXXCDNBCFYJQY-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-4-methyl-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=C(C)C=CC=C3NC2=O)=C1C MUXXCDNBCFYJQY-UHFFFAOYSA-N 0.000 description 1
BCMUPCKWGCURKL-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-5-methoxy-1h-indol-2-one Chemical compound C12=CC(OC)=CC=C2NC(=O)C1=CC=1NC(C)=C(CCCN(C)C)C=1C BCMUPCKWGCURKL-UHFFFAOYSA-N 0.000 description 1
MQGRHUQMDUWCTN-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-5-methyl-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(C)=CC=C3NC2=O)=C1C MQGRHUQMDUWCTN-UHFFFAOYSA-N 0.000 description 1
QZNBWVZFYJHFCN-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-5-morpholin-4-ylsulfonyl-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(=CC=C3NC2=O)S(=O)(=O)N2CCOCC2)=C1C QZNBWVZFYJHFCN-UHFFFAOYSA-N 0.000 description 1
AGYUVURRUUXGGG-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-6-(4-methoxyphenyl)-1h-indol-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC2=C(C(CCCN(C)C)=C(C)N2)C)C(=O)N2)C2=C1 AGYUVURRUUXGGG-UHFFFAOYSA-N 0.000 description 1
VTRZRDRDYBDPQL-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-6-phenyl-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC=C(C=C3NC2=O)C=2C=CC=CC=2)=C1C VTRZRDRDYBDPQL-UHFFFAOYSA-N 0.000 description 1
HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
JRQDVRIQJJPHEQ-UHFFFAOYSA-N 3970-35-2 Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1Cl JRQDVRIQJJPHEQ-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
PTNLMYKCABVKOZ-UHFFFAOYSA-N 4,5-dimethoxy-1,3-dihydroindol-2-one Chemical compound COC1=CC=C2NC(=O)CC2=C1OC PTNLMYKCABVKOZ-UHFFFAOYSA-N 0.000 description 1
QRTHVOUKWCEPKJ-UHFFFAOYSA-N 4-(2-hydroxyethyl)-1,3-dihydroindol-2-one Chemical compound OCCC1=CC=CC2=C1CC(=O)N2 QRTHVOUKWCEPKJ-UHFFFAOYSA-N 0.000 description 1
URUYZLLTRAUSHV-UHFFFAOYSA-N 4-[(2-oxo-1,3-dihydroindol-5-yl)carbamoyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)NC1=CC=C(NC(=O)C2)C2=C1 URUYZLLTRAUSHV-UHFFFAOYSA-N 0.000 description 1
ZYSKQDWGVBAZAE-UHFFFAOYSA-N 4-[2-(2-propan-2-ylphenoxy)ethyl]-1,3-dihydroindol-2-one Chemical class CC(C)C1=CC=CC=C1OCCC1=CC=CC2=C1CC(=O)N2 ZYSKQDWGVBAZAE-UHFFFAOYSA-N 0.000 description 1
GDZVODBMOJRKRS-UHFFFAOYSA-N 4-[2-(3-propan-2-ylphenoxy)ethyl]-1,3-dihydroindol-2-one Chemical class CC(C)C1=CC=CC(OCCC=2C=3CC(=O)NC=3C=CC=2)=C1 GDZVODBMOJRKRS-UHFFFAOYSA-N 0.000 description 1
XTEAGYUOVWCQGA-UHFFFAOYSA-N 4-[2-(4-propan-2-ylphenoxy)ethyl]-1,3-dihydroindol-2-one Chemical class C1=CC(C(C)C)=CC=C1OCCC1=CC=CC2=C1CC(=O)N2 XTEAGYUOVWCQGA-UHFFFAOYSA-N 0.000 description 1
TVGJPIIDWGXRAG-UHFFFAOYSA-N 4-[3-(2,4-dimethyl-1h-pyrrol-3-yl)propyl]morpholine Chemical compound CC1=CNC(C)=C1CCCN1CCOCC1 TVGJPIIDWGXRAG-UHFFFAOYSA-N 0.000 description 1
YSGWLWLRMYTFIK-UHFFFAOYSA-N 4-butanoyl-1,3-dihydroindol-2-one Chemical compound CCCC(=O)C1=CC=CC2=C1CC(=O)N2 YSGWLWLRMYTFIK-UHFFFAOYSA-N 0.000 description 1
ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
GKODDAXOSGGARJ-UHFFFAOYSA-N 5-Fluoroisatin Chemical compound FC1=CC=C2NC(=O)C(=O)C2=C1 GKODDAXOSGGARJ-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
FIYRYZIFOKMBOE-UHFFFAOYSA-N 5-butanoyl-1,3-dihydroindol-2-one Chemical compound CCCC(=O)C1=CC=C2NC(=O)CC2=C1 FIYRYZIFOKMBOE-UHFFFAOYSA-N 0.000 description 1
WESRTMMUHCBTED-UHFFFAOYSA-N 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1h-pyrrol-2-yl]methylidene]-1h-indol-2-one Chemical compound CN(C)CCCC1=C(C)NC(C=C2C3=CC(Cl)=CC=C3NC2=O)=C1C WESRTMMUHCBTED-UHFFFAOYSA-N 0.000 description 1
FYMGXBGSTYKVGE-UHFFFAOYSA-N 5-iodo-4-methyl-1,3-dihydroindol-2-one Chemical compound C1=C(I)C(C)=C2CC(=O)NC2=C1 FYMGXBGSTYKVGE-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
ONVQJRUWAVVUHE-UHFFFAOYSA-N 6-[3-(2,2,2-trifluoroacetyl)phenyl]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C(=O)C1=CC=CC(C=2C=C3NC(=O)CC3=CC=2)=C1 ONVQJRUWAVVUHE-UHFFFAOYSA-N 0.000 description 1
PHKHSQVVCIIMNR-UHFFFAOYSA-N 6-morpholin-4-yl-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC=C1N1CCOCC1 PHKHSQVVCIIMNR-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000182988 Assa Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
240000006497 Dianthus caryophyllus Species 0.000 description 1
235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
208000032027 Essential Thrombocythemia Diseases 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
101000851005 Mus musculus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
MKBYLRYHZMDKGY-UHFFFAOYSA-N N[N+](C([O-])=O)(C#N)[N+]([O-])=O Chemical compound N[N+](C([O-])=O)(C#N)[N+]([O-])=O MKBYLRYHZMDKGY-UHFFFAOYSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
101150038994 PDGFRA gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
102000004422 Phospholipase C gamma Human genes 0.000 description 1
108010056751 Phospholipase C gamma Proteins 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
FMSRMLMJROGIGA-UHFFFAOYSA-N [Na].CC=1C(=CNC1C=C1C(NC2=CC=CC=C12)=O)CCC(=O)O Chemical compound [Na].CC=1C(=CNC1C=C1C(NC2=CC=CC=C12)=O)CCC(=O)O FMSRMLMJROGIGA-UHFFFAOYSA-N 0.000 description 1
USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
AIRISBCKFSLMOW-UHFFFAOYSA-N acetic acid;1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound CC(O)=O.C1=CN=C2NC(=O)CC2=C1 AIRISBCKFSLMOW-UHFFFAOYSA-N 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000001656 angiogenetic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000021592 benign granular cell tumor Diseases 0.000 description 1
ZIQCCIAIROIHHR-UHFFFAOYSA-N benzene;boric acid Chemical compound OB(O)O.C1=CC=CC=C1 ZIQCCIAIROIHHR-UHFFFAOYSA-N 0.000 description 1
229950005567 benzodepa Drugs 0.000 description 1
VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000006229 carbon black Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
208000015100 cartilage disease Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
239000003245 coal Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
230000006552 constitutive activation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
KPUNOVLMCQQCSK-UHFFFAOYSA-N diazomethane;ethoxyethane Chemical compound C=[N+]=[N-].CCOCC KPUNOVLMCQQCSK-UHFFFAOYSA-N 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
MBAQGFLNQDHQCE-UHFFFAOYSA-N dimethyl 2-[2-nitro-4-(trifluoromethyl)phenyl]propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O MBAQGFLNQDHQCE-UHFFFAOYSA-N 0.000 description 1
QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001548 drop coating Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002888 effect on disease Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
ZYNJVGCLOFPWFZ-UHFFFAOYSA-N ethyl 4-(3-ethoxy-3-oxopropyl)-3,5-dimethyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)CCC1=C(C)NC(C(=O)OCC)=C1C ZYNJVGCLOFPWFZ-UHFFFAOYSA-N 0.000 description 1
GDISALBEIGGPER-UHFFFAOYSA-N ethyl 5-formyl-2,4-dimethyl-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(C=O)=C1C GDISALBEIGGPER-UHFFFAOYSA-N 0.000 description 1
XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
238000005187 foaming Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
101150098203 grb2 gene Proteins 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000003667 hormone antagonist Substances 0.000 description 1
102000058223 human VEGFA Human genes 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
229950008097 improsulfan Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
XLKMOMJQAMBSRB-UHFFFAOYSA-N methyl 3-[1-[(3-fluorophenyl)methyl]-5-formyl-2,4-dimethylpyrrol-3-yl]propanoate Chemical compound CC1=C(CCC(=O)OC)C(C)=C(C=O)N1CC1=CC=CC(F)=C1 XLKMOMJQAMBSRB-UHFFFAOYSA-N 0.000 description 1
CVXXHXPNTZBZEL-UHFFFAOYSA-N methyl 4-carbonochloridoylbenzoate Chemical compound COC(=O)C1=CC=C(C(Cl)=O)C=C1 CVXXHXPNTZBZEL-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
229950009847 meturedepa Drugs 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
201000004130 myoblastoma Diseases 0.000 description 1
SBULNBMWGLBIMA-UHFFFAOYSA-N n,n-dimethyl-2-oxo-1,3-dihydroindole-5-sulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C2NC(=O)CC2=C1 SBULNBMWGLBIMA-UHFFFAOYSA-N 0.000 description 1
WJBXUAIGXKXYLO-UHFFFAOYSA-N n-(4-fluorophenyl)-3-(5-formyl-1,2,4-trimethylpyrrol-3-yl)propanamide Chemical compound CN1C(C=O)=C(C)C(CCC(=O)NC=2C=CC(F)=CC=2)=C1C WJBXUAIGXKXYLO-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
101150009274 nhr-1 gene Proteins 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000021231 nutrient uptake Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229940078552 o-xylene Drugs 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
125000001477 organic nitrogen group Chemical group 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002642 osteogeneic effect Effects 0.000 description 1
229940045681 other alkylating agent in atc Drugs 0.000 description 1
229940127075 other antimetabolite Drugs 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
229950001100 piposulfan Drugs 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical class O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
230000027272 reproductive process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229950000366 roxindole Drugs 0.000 description 1
238000007790 scraping Methods 0.000 description 1
150000003346 selenoethers Chemical class 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
240000003177 tenweeks stock Species 0.000 description 1
JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
229950006929 uredepa Drugs 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2

NO20005916A 1998-05-29 2000-11-22 Pyrrolsubstituert 2-indolinon protein kinase inhibitorer NO318083B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8731098P	1998-05-29	1998-05-29
US11610699P	1999-01-15	1999-01-15
PCT/US1999/012069 WO1999061422A1 (en)	1998-05-29	1999-05-28	Pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (3)

Publication Number	Publication Date
NO20005916D0 NO20005916D0 (no)	2000-11-22
NO20005916L NO20005916L (no)	2001-01-29
NO318083B1 true NO318083B1 (no)	2005-01-31

Family

ID=26776832

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20005916A NO318083B1 (no)	1998-05-29	2000-11-22	Pyrrolsubstituert 2-indolinon protein kinase inhibitorer

Country Status (24)

Country	Link
US (2)	US6395734B1 (pt)
EP (2)	EP2020408B1 (pt)
JP (1)	JP4528440B2 (pt)
KR (1)	KR100743287B1 (pt)
CN (1)	CN1250526C (pt)
AR (1)	AR018408A1 (pt)
AU (1)	AU759226B2 (pt)
BR (1)	BR9910792A (pt)
CA (1)	CA2314156C (pt)
CO (1)	CO5031249A1 (pt)
DK (1)	DK2020408T3 (pt)
EA (1)	EA005032B1 (pt)
ES (1)	ES2429573T3 (pt)
HK (1)	HK1126770A1 (pt)
HU (1)	HUP0103617A2 (pt)
IL (2)	IL139934A0 (pt)
NO (1)	NO318083B1 (pt)
NZ (1)	NZ508815A (pt)
PL (1)	PL344477A1 (pt)
PT (1)	PT2020408E (pt)
SK (1)	SK287132B6 (pt)
TR (1)	TR200003514T2 (pt)
TW (1)	TWI229073B (pt)
WO (1)	WO1999061422A1 (pt)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6906093B2 (en) *	1995-06-07	2005-06-14	Sugen, Inc.	Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US6316429B1 (en) *	1997-05-07	2001-11-13	Sugen, Inc.	Bicyclic protein kinase inhibitors
US6051593A (en) *	1997-06-20	2000-04-18	Sugen, Inc.	3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6569868B2 (en)	1998-04-16	2003-05-27	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
HUP0103617A2 (hu) *	1998-05-29	2002-02-28	Sugen, Inc.	Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
BR9916327A (pt)	1998-12-17	2001-09-18	Hoffmann La Roche	Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
EP1149093A1 (en)	1998-12-17	2001-10-31	F. Hoffmann-La Roche Ag	4-aryloxindoles as inhibitors of jnk protein kinases
US6153634A (en) *	1998-12-17	2000-11-28	Hoffmann-La Roche Inc.	4,5-azolo-oxindoles
US20030119895A1 (en) *	1998-12-23	2003-06-26	Pharmacia Corporation	Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US6689806B1 (en) *	1999-03-24	2004-02-10	Sugen, Inc.	Indolinone compounds as kinase inhibitors
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6878733B1 (en)	1999-11-24	2005-04-12	Sugen, Inc.	Formulations for pharmaceutical agents ionizable as free acids or free bases
WO2001037820A2 (en) *	1999-11-24	2001-05-31	Sugen, Inc.	Ionizable indolinone derivatives and their use as ptk ligands
US6313310B1 (en)	1999-12-15	2001-11-06	Hoffmann-La Roche Inc.	4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
CA2395461C (en) *	1999-12-22	2010-05-25	Sugen, Inc.	Methods of modulating c-kit tyrosine kinase function with indolinone compounds
US6339100B1 (en) *	1999-12-29	2002-01-15	The Trustees Of Columbia University In The City Of New York	Methods for inhibiting mastocytosis
EP1259234B9 (en) *	1999-12-30	2007-02-14	Sugen, Inc.	3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
CA2399358C (en) *	2000-02-15	2006-03-21	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors
CA2407799A1 (en)	2000-05-02	2001-11-08	Sugen, Inc.	(2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en)	2000-05-24	2007-02-28	Upjohn Co	1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en)	2000-06-02	2003-03-26	Sugen, Inc.	Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002002551A1 (en) *	2000-06-30	2002-01-10	Sugen, Inc.	4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP2004518669A (ja)	2000-12-20	2004-06-24	スージェン・インコーポレーテッド	４−アリール置換インドリノン
AR032028A1 (es)	2001-01-05	2003-10-22	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR042586A1 (es)	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2004529110A (ja)	2001-03-06	2004-09-24	アストラゼネカアクチボラグ	脈管損傷活性を有するインドール誘導体
WO2002081466A1 (en) *	2001-04-09	2002-10-17	Sugen, Inc.	Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2448076A1 (en) *	2001-05-24	2002-11-28	Masahiko Hayakawa	3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
US6599902B2 (en)	2001-05-30	2003-07-29	Sugen, Inc.	5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2003000194A2 (en)	2001-06-21	2003-01-03	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
JP2005500041A (ja)	2001-06-29	2005-01-06	アブサイエンス	強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
JP2004537542A (ja)	2001-06-29	2004-12-16	アブサイエンス	炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
JP2004530722A (ja) *	2001-06-29	2004-10-07	アブサイエンス	骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
DE60212627T2 (de) *	2001-06-29	2007-06-14	Ab Science	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung von entzündlichen Krankheiten
EP1401413B1 (en)	2001-06-29	2006-11-22	AB Science	Use of tyrosine kinase inhibitions for treating allergic diseases
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer
JP2005508953A (ja)	2001-10-10	2005-04-07	スージェン・インコーポレーテッド	キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
TWI259081B (en) *	2001-10-26	2006-08-01	Sugen Inc	Treatment of acute myeloid leukemia with indolinone compounds
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
AU2002360753B2 (en) *	2001-12-27	2008-08-21	Theravance, Inc.	Indolinone derivatives useful as protein kinase inhibitors
MXPA04008403A (es)	2002-03-01	2004-11-26	Pfizer	Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
EP1501357A4 (en) *	2002-05-06	2009-10-21	Genentech Inc	USE OF VEGF FOR THE TREATMENT OF BONE DEFECTS
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004000915A2 (en)	2002-06-24	2003-12-31	Tufts University	Silk biomaterials and methods of use thereof
US20050032871A1 (en) *	2002-09-03	2005-02-10	Sugen, Inc.	Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
AR042042A1 (es) *	2002-11-15	2005-06-08	Sugen Inc	Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7626031B2 (en)	2002-11-15	2009-12-01	Symphony Evolution, Inc.	Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
AU2003284572A1 (en) *	2002-11-22	2004-06-18	Yamanouchi Pharmaceutical Co., Ltd.	2-oxoindoline derivatives
JP4879492B2 (ja) *	2002-11-27	2012-02-22	アラーガン、インコーポレイテッド	疾患の治療のためのキナーゼ阻害剤
JP3814285B2 (ja)	2002-12-19	2006-08-23	ファイザー・インク	眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
GEP20084341B (en)	2003-02-26	2008-03-25	Sugen Inc	Aminoheteroaryl compounds as protein kinase inhibitors
US7157577B2 (en) *	2003-03-07	2007-01-02	Sugen Inc.	5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) *	2003-03-07	2004-12-30	Sugen, Inc.	Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
EP3231846A1 (en)	2003-04-10	2017-10-18	Tufts University	Concentrated aqueous silk fibroin solution and use thereof
JP5105874B2 (ja)	2003-07-18	2012-12-26	アムジエン・インコーポレーテツド	肝細胞増殖因子に対する特異的結合因子
BRPI0413281A (pt) *	2003-08-06	2006-10-10	Sugen Inc	3-ciclopentilideno-1,3,dihidroindol-2-onas geometricamente restringidas como potentes inibidores de proteìna cinase
DE602004017479D1 (de)	2003-08-29	2008-12-11	Pfizer	Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
MXPA06004438A (es)	2003-10-24	2006-06-20	Schering Ag	Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
WO2005051919A1 (en) *	2003-11-26	2005-06-09	Pfizer Products Inc.	Aminopyrazole derivatives as gsk-3 inhibitors
BRPI0418102A (pt)	2003-12-23	2007-04-27	Pfizer	derivados de quinolina
CA2571421A1 (en)	2004-06-24	2006-01-05	Nicholas Valiante	Compounds for immunopotentiation
ATE463486T1 (de)	2004-08-26	2010-04-15	Pfizer	Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
GT200500321A (es)	2004-11-09	2006-09-04		Compuestos y composiciones como inhibidores de proteina kinase.
EP1827434B1 (en)	2004-11-30	2014-01-15	Amgen Inc.	Quinolines and quinazoline analogs and their use as medicaments for treating cancer
DE602006016085D1 (de)	2005-03-16	2010-09-23	Genentech Inc	Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
NZ562453A (en)	2005-03-31	2010-04-30	Agensys Inc	Antibodies and related molecules that bind to 161P2F10B proteins
BRPI0608096A2 (pt)	2005-04-26	2009-11-10	Pfizer	anticorpos p-caderina
EP1883403A4 (en) *	2005-04-29	2011-02-16	Univ Ohio State Res Found	KERATINOCYTE GROWTH FACTOR RECEPTOR TYROSINE-SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTASE
UA94060C2 (ru)	2005-09-07	2011-04-11	Эмджен Фримонт Инк.	Моноклональное антитело, которое специфически связывает alk-1
WO2007035744A1 (en)	2005-09-20	2007-03-29	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20080108664A1 (en)	2005-12-23	2008-05-08	Liu Belle B	Solid-state form of AMG 706 and pharmaceutical compositions thereof
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
WO2007085188A1 (en)	2006-01-27	2007-08-02	Shanghai Hengrui Pharmaceutical Co. Ltd.	Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
AU2007212696B2 (en)	2006-02-10	2011-05-19	Amgen Inc.	Hydrate forms of AMG706
KR100647350B1 (ko) *	2006-04-03	2006-11-23	김상민	시밍장치
TW200808739A (en)	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
CN101472915A (zh)	2006-04-19	2009-07-01	诺瓦提斯公司	吲唑化合物和抑制cdc7的方法
EA200802058A1 (ru)	2006-05-09	2009-06-30	Пфайзер Продактс Инк.	Производные циклоалкиламинокислот и их фармацевтические композиции
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es)	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
US20100028451A1 (en)	2006-09-26	2010-02-04	Trustees Of Tufts College	Silk microspheres for encapsulation and controlled release
CA2665007A1 (en) *	2006-10-06	2008-05-08	Merck & Co., Inc.	Non-nucleoside reverse transcriptase inhibitors
AU2007338792B2 (en)	2006-12-20	2012-05-31	Amgen Inc.	Substituted heterocycles and methods of use
US7759344B2 (en)	2007-01-09	2010-07-20	Amgen Inc.	Bis-aryl amide derivatives and methods of use
WO2008103277A2 (en)	2007-02-16	2008-08-28	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP2010522583A (ja)	2007-02-27	2010-07-08	トラスティーズオブタフツカレッジ	組織工学的に作製された絹製臓器
US8642067B2 (en)	2007-04-02	2014-02-04	Allergen, Inc.	Methods and compositions for intraocular administration to treat ocular conditions
JP5926487B2 (ja)	2007-04-13	2016-05-25	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	ＥｒｂＢ療法に耐性である癌を治療するための方法
WO2009023615A1 (en)	2007-08-10	2009-02-19	Trustees Of Tufts College	Tubular silk compositions and methods of use thereof
CL2008002444A1 (es)	2007-08-21	2009-09-04	Amgen Inc	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
WO2009030270A1 (en) *	2007-09-03	2009-03-12	Novartis Ag	Dihydroindole derivatives useful in parkinson's disease
CN101952282A (zh)	2007-12-20	2011-01-19	诺瓦提斯公司	用作pi 3激酶抑制剂的噻唑衍生物
US8993615B2 (en) *	2008-08-08	2015-03-31	The Johns Hopkins University	Compositions and methods for treatment of neurodegenerative disease
CA2737597C (en)	2008-10-16	2017-03-14	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
CN101397295B (zh) *	2008-11-12	2012-04-25	深圳微芯生物科技有限责任公司	作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
SG172857A1 (en)	2009-02-09	2011-08-29	Supergen Inc	Pyrrolopyrimidinyl axl kinase inhibitors
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2010099137A2 (en)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US20100222381A1 (en)	2009-02-27	2010-09-02	Hariprasad Vankayalapati	Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
SG10201510152RA (en)	2009-07-13	2016-01-28	Genentech Inc	Diagnostic methods and compositions for treatment of cancer
WO2011014726A1 (en)	2009-07-31	2011-02-03	Osi Pharmaceuticals, Inc.	Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011027249A2 (en)	2009-09-01	2011-03-10	Pfizer Inc.	Benzimidazole derivatives
AU2010292060A1 (en)	2009-09-11	2012-04-12	Genentech, Inc.	Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
CN102612566B (zh)	2009-09-17	2016-02-17	霍夫曼-拉罗奇有限公司	用于癌症患者中诊断学用途的方法和组合物
WO2011073521A1 (en)	2009-12-15	2011-06-23	Petri Salven	Methods for enriching adult-derived endothelial progenitor cells and uses thereof
TWI402265B (zh)	2009-12-25	2013-07-21	Taiho Pharmaceutical Co Ltd	A Method for Predicting the Therapeutic Effect of Chemotherapy for Patients with Hepatocellular Carcinoma
EP2517707A4 (en)	2009-12-25	2013-06-12	Taiho Pharmaceutical Co Ltd	ANTITUM REAGENT OR POSTOPERATIVE ADJUVANT CHEMOTHERAPEUTIC FOR THE TREATMENT OF LIVER CELL CARCINOMA
WO2011098971A1 (en)	2010-02-12	2011-08-18	Pfizer Inc.	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US20110217309A1 (en)	2010-03-03	2011-09-08	Buck Elizabeth A	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2013527748A (ja)	2010-03-03	2013-07-04	オーエスアイ・ファーマシューティカルズ，エルエルシー	インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
WO2011153224A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
ES2611479T3 (es)	2010-06-16	2017-05-09	University Of Pittsburgh- Of The Commonwealth System Of Higher Education	Anticuerpos contra endoplasmina y su uso
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
JP2013538338A (ja)	2010-07-19	2013-10-10	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	抗癌治療への応答可能性の増大した患者を同定する方法
SG187018A1 (en)	2010-07-19	2013-02-28	Hoffmann La Roche	Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012012750A1 (en)	2010-07-23	2012-01-26	Trustees Of Boston University	ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012042421A1 (en)	2010-09-29	2012-04-05	Pfizer Inc.	Method of treating abnormal cell growth
EP2630134B9 (en)	2010-10-20	2018-04-18	Pfizer Inc	Pyridine-2- derivatives as smoothened receptor modulators
AP2013007043A0 (en)	2011-01-31	2013-08-31	Novartis Ag	Novel heterocyclic derivatives
US20120214830A1 (en)	2011-02-22	2012-08-23	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
DK2688887T3 (en)	2011-03-23	2015-06-29	Amgen Inc	DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
EP2699598B1 (en)	2011-04-19	2019-03-06	Pfizer Inc	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012145652A1 (en)	2011-04-20	2012-10-26	Trustees Of Tufts College	Dynamic silk coatings for implantable devices
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2671748T3 (es)	2011-07-21	2018-06-08	Tolero Pharmaceuticals, Inc.	Inhibidores heterocíclicos de proteína quinasas
US9745288B2 (en)	2011-08-16	2017-08-29	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2013042006A1 (en)	2011-09-22	2013-03-28	Pfizer Inc.	Pyrrolopyrimidine and purine derivatives
EP3275902A1 (en)	2011-10-04	2018-01-31	IGEM Therapeutics Limited	Ige anti-hmw-maa antibody
WO2013061305A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Novel purine derivatives and their use in the treatment of disease
BR112014011115A2 (pt)	2011-11-08	2017-06-13	Pfizer	métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2867464A1 (en)	2012-03-20	2013-09-26	Trustees Of Tufts College	Silk reservoirs for drug delivery
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
EP2836236B1 (en)	2012-04-13	2019-01-02	Trustees Of Tufts College	Methods and compositions for preparing a silk microsphere
EP2838538B1 (en) *	2012-04-20	2017-03-15	Annji Pharmaceutical Co., Ltd.	Cyclopropanecarboxylate esters of purine analogues
JP6381523B2 (ja)	2012-05-16	2018-08-29	ノバルティスアーゲー	Ｐｉ−３キナーゼ阻害剤の投与レジメン
US10034945B2 (en)	2012-07-13	2018-07-31	Trustees Of Tufts College	Silk powder compaction for production of constructs with high mechanical strength and stiffness
US9505749B2 (en)	2012-08-29	2016-11-29	Amgen Inc.	Quinazolinone compounds and derivatives thereof
US9394257B2 (en)	2012-10-16	2016-07-19	Tolero Pharmaceuticals, Inc.	PKM2 modulators and methods for their use
CN102887851B (zh) *	2012-11-02	2014-03-19	天津希恩思生化科技有限公司	化合物3,5-二甲基-1h-吡咯-2,4-二甲醛及其制备方法
US9260426B2 (en)	2012-12-14	2016-02-16	Arrien Pharmaceuticals Llc	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US10202356B2 (en)	2013-03-14	2019-02-12	Tolero Pharmaceuticals, Inc.	JAK2 and ALK2 inhibitors and methods for their use
JP6457482B2 (ja)	2013-03-15	2019-01-23	トラスティーズオブタフツカレッジ	低分子量絹組成物および絹組成物の安定化
US11376329B2 (en)	2013-03-15	2022-07-05	Trustees Of Tufts College	Low molecular weight silk compositions and stabilizing silk compositions
US9206188B2 (en)	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2014176458A2 (en)	2013-04-24	2014-10-30	Trustees Of Tufts College	Bioresorbable biopolymer anastomosis devices
DK3052102T3 (da)	2013-10-04	2020-03-09	Aptose Biosciences Inc	Sammensætninger til behandling af cancere
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
JP2016539149A (ja)	2013-12-06	2016-12-15	ノバルティスアーゲー	アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
CN111808957A (zh)	2014-04-04	2020-10-23	中美冠科生物技术（太仓）有限公司	用于确定对mek/erk抑制剂的应答性的方法
WO2015155624A1 (en)	2014-04-10	2015-10-15	Pfizer Inc.	Dihydropyrrolopyrimidine derivatives
PT3137460T (pt)	2014-04-30	2019-12-30	Pfizer	Derivados de di-heterociclo ligado a cicloalquilo
WO2016001789A1 (en)	2014-06-30	2016-01-07	Pfizer Inc.	Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
ES2848857T3 (es)	2014-07-31	2021-08-12	Us Gov Health & Human Services	Anticuerpos monoclonales humanos contra EphA4 y su uso
WO2016100721A1 (en)	2014-12-17	2016-06-23	Tufts University	Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
ES2746839T3 (es)	2014-12-18	2020-03-09	Pfizer	Derivados de pirimidina y triazina y su uso como inhibidores de AXL
EP3242934B1 (en)	2015-01-08	2021-08-18	The Board of Trustees of the Leland Stanford Junior University	Factors and cells that provide for induction of bone, bone marrow, and cartilage
MX2017013383A (es)	2015-04-20	2017-12-07	Tolero Pharmaceuticals Inc	Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
US10011629B2 (en)	2015-05-01	2018-07-03	Cocrystal Pharma, Inc.	Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
KR102608921B1 (ko)	2015-05-18	2023-12-01	스미토모 파마 온콜로지, 인크.	생체 이용률이 증가된 알보시딥 프로드러그
WO2017009751A1 (en)	2015-07-15	2017-01-19	Pfizer Inc.	Pyrimidine derivatives
US20200078495A1 (en)	2015-07-20	2020-03-12	Tufts University	Biodegradable silk ear tubes
MX2018001289A (es)	2015-08-03	2018-04-30	Tolero Pharmaceuticals Inc	Terapias de combinacion para el tratamiento del cancer.
AU2016347881A1 (en)	2015-11-02	2018-05-10	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
JP6877429B2 (ja)	2015-12-03	2021-05-26	アジオスファーマシューティカルズ，インコーポレイテッド	Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
WO2017189832A1 (en)	2016-04-29	2017-11-02	Trustees Of Tufts College	An artificial silk based innervated cornea
US11298443B2 (en)	2016-07-01	2022-04-12	Trustees Of Tufts College	Innervated artificial skin
US11248313B2 (en)	2016-08-01	2022-02-15	Trustees Of Tufts College	Biomimetic mechanical tension driven fabrication of nanofibrillar architecture
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
US10132797B2 (en)	2016-12-19	2018-11-20	Tolero Pharmaceuticals, Inc.	Profiling peptides and methods for sensitivity profiling
RS62456B1 (sr)	2016-12-22	2021-11-30	Amgen Inc	Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
US20200000713A1 (en)	2017-01-20	2020-01-02	Massachusetts Institute Of Technology	Injectable polymer micro-depots for controlled local drug delivery
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
SG11202001499WA (en)	2017-09-08	2020-03-30	Amgen Inc	Inhibitors of kras g12c and methods of using the same
WO2019055579A1 (en)	2017-09-12	2019-03-21	Tolero Pharmaceuticals, Inc.	TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US20200237766A1 (en)	2017-10-13	2020-07-30	Tolero Pharmaceuticals, Inc.	Pkm2 activators in combination with reactive oxygen species for treatment of cancer
US11419947B2 (en)	2017-10-30	2022-08-23	Massachusetts Institute Of Technology	Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
US20210236644A1 (en)	2017-11-10	2021-08-05	Cocoon Biotech Inc.	Ocular applications of silk-based products
EP3788038B1 (en)	2018-05-04	2023-10-11	Amgen Inc.	Kras g12c inhibitors and methods of using the same
US11045484B2 (en)	2018-05-04	2021-06-29	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
WO2019217691A1 (en)	2018-05-10	2019-11-14	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en)	2018-06-01	2021-08-24	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
EP3802537A1 (en)	2018-06-11	2021-04-14	Amgen Inc.	Kras g12c inhibitors for treating cancer
MX2020012261A (es)	2018-06-12	2021-03-31	Amgen Inc	Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3117222A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MX2021006544A (es)	2018-12-04	2021-07-07	Sumitomo Pharma Oncology Inc	Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MA54547A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
PE20211475A1 (es)	2018-12-20	2021-08-05	Amgen Inc	Inhibidores de kif18a
MA54546A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
ES2953821T3 (es)	2018-12-20	2023-11-16	Amgen Inc	Inhibidores de KIF18A
EP3924351A4 (en)	2019-02-12	2022-12-21	Sumitomo Pharma Oncology, Inc.	FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
JP2022522777A (ja)	2019-03-01	2022-04-20	レボリューションメディシンズインコーポレイテッド	二環式ヘテロアリール化合物及びその使用
US20230096028A1 (en)	2019-03-01	2023-03-30	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
WO2020191326A1 (en)	2019-03-20	2020-09-24	Sumitomo Dainippon Pharma Oncology, Inc.	Treatment of acute myeloid leukemia (aml) with venetoclax failure
AU2020245437A1 (en)	2019-03-22	2021-09-30	Sumitomo Pharma Oncology, Inc.	Compositions comprising PKM2 modulators and methods of treatment using the same
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en)	2019-05-21	2022-03-30	Amgen Inc.	Solid state forms
CA3142608A1 (en)	2019-06-04	2020-12-10	Cocoon Biotech Inc.	Silk-based products, formulations, and methods of use
CN114401953A (zh)	2019-08-02	2022-04-26	美国安进公司	Kif18a抑制剂
AU2020324963A1 (en)	2019-08-02	2022-02-24	Amgen Inc.	KIF18A inhibitors
WO2021026098A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
US20220372018A1 (en)	2019-08-02	2022-11-24	Amgen Inc.	Kif18a inhibitors
WO2021081212A1 (en)	2019-10-24	2021-04-29	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
EP4054719A1 (en)	2019-11-04	2022-09-14	Revolution Medicines, Inc.	Ras inhibitors
TW202132314A (zh)	2019-11-04	2021-09-01	美商銳新醫藥公司	Ｒａｓ抑制劑
CA3159559A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
PE20230249A1 (es)	2019-11-08	2023-02-07	Revolution Medicines Inc	Compuestos de heteroarilo biciclicos y usos de estos
WO2021097212A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
AR120456A1 (es)	2019-11-14	2022-02-16	Amgen Inc	Síntesis mejorada del compuesto inhibidor de g12c de kras
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
BR112022010086A2 (pt)	2020-01-07	2022-09-06	Revolution Medicines Inc	Dosagem do inibidor de shp2 e métodos de tratamento de câncer
WO2021155006A1 (en)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibitors of cyclin-dependent kinases and uses thereof
CN115916194A (zh)	2020-06-18	2023-04-04	锐新医药公司	用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
AU2021344830A1 (en)	2020-09-03	2023-04-06	Revolution Medicines, Inc.	Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko)	2020-09-15	2023-05-16	레볼루션 메디슨즈, 인크.	암의 치료에서 ras 억제제로서 인돌 유도체
CN112661639A (zh) *	2020-12-07	2021-04-16	浙江工业大学	一种4-乙酰丁酸酯类化合物合成方法
CN117396472A (zh)	2020-12-22	2024-01-12	上海齐鲁锐格医药研发有限公司	Sos1抑制剂及其用途
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
WO2022235870A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Ras inhibitors for the treatment of cancer
CR20230570A (es)	2021-05-05	2024-01-22	Revolution Medicines Inc	Inhibidores de ras
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023081923A1 (en)	2021-11-08	2023-05-11	Frequency Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202340214A (zh)	2021-12-17	2023-10-16	美商健臻公司	做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
US20230399313A1 (en) *	2022-06-10	2023-12-14	Advenchen Pharmaceuticals, LLC	Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024081916A1 (en)	2022-10-14	2024-04-18	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3308134A (en)	1965-10-22	1967-03-07	Mcneilab Inc	Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3859693A (en)	1973-06-12	1975-01-14	Charles P Breed	Sliding snap shackle
US4002749A (en)	1975-08-12	1977-01-11	E. R. Squibb & Sons, Inc.	Substituted indolinones
US4053613A (en)	1975-09-17	1977-10-11	E. R. Squibb & Sons, Inc.	1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
US4966849A (en)	1985-09-20	1990-10-30	President And Fellows Of Harvard College	CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
CA1284681C (en)	1986-07-09	1991-06-04	Alcan International Limited	Methods and apparatus for the detection and correction of roll eccentricity in rolling mills
US5217999A (en)	1987-12-24	1993-06-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Styryl compounds which inhibit EGF receptor protein tyrosine kinase
GB9004483D0 (en)	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
DE69105495T2 (de)	1990-04-02	1995-04-06	Pfizer	Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en)	1990-04-16	1994-04-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
WO1992007830A2 (en)	1990-10-29	1992-05-14	Pfizer Inc.	Oxindole peptide antagonists
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06503095A (ja)	1991-05-29	1994-04-07	ファイザー・インコーポレーテッド	三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
EP0641204B1 (en)	1992-05-20	2000-08-16	Merck & Co. Inc.	17-ethers and thioethers of 4-aza-steroids
HUT71553A (en)	1992-08-06	1995-12-28	Warner Lambert Co	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en)	1992-10-23	1994-07-19	Sterling Winthrop Inc.	1-cyclopropyl-4-pyridyl-quinolinones
CA2145985C (en)	1992-10-28	2003-09-16	Napoleone Ferrara	Vascular endothelial cell growth factor antagonists
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9226855D0 (en)	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en)	1994-06-24	1994-08-17	Erba Carlo Spa	Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en)	1994-11-28	1995-01-11	Erba Carlo Spa	Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en)	1995-01-26	1995-03-15	Pharmacia Spa	Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5786488A (en)	1996-11-13	1998-07-28	Sugen, Inc.	Synthetic methods for the preparation of indolyquinones
WO1998007835A2 (en)	1996-08-21	1998-02-26	Sugen, Inc.	Crystal structures of a protein tyrosine kinase
EP1247803A3 (en)	1996-08-23	2002-10-16	Sugen, Inc.	Indolinone compounds suitable for modulation of protein kinases
AU7622698A (en)	1996-12-05	1998-06-29	Sugen, Inc.	Use of indolinone compounds as modulators of protein kinases
ATE554750T1 (de)	1997-03-05	2012-05-15	Sugen Inc	Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
WO1998045708A1 (en)	1997-04-08	1998-10-15	Sugen, Inc.	Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
CA2289102A1 (en) *	1997-05-07	1998-11-12	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
WO1998056376A1 (en)	1997-06-13	1998-12-17	Sugen, Inc.	Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP2002507598A (ja)	1998-03-26	2002-03-12	スージェン・インコーポレーテッド	チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
HUP0103617A2 (hu) *	1998-05-29	2002-02-28	Sugen, Inc.	Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása

1999
- 1999-05-28 HU HU0103617A patent/HUP0103617A2/hu not_active Application Discontinuation
- 1999-05-28 IL IL13993499A patent/IL139934A0/xx active IP Right Grant
- 1999-05-28 JP JP2000550828A patent/JP4528440B2/ja not_active Expired - Fee Related
- 1999-05-28 IL IL139934A patent/IL139934A/en not_active IP Right Cessation
- 1999-05-28 KR KR1020007013863A patent/KR100743287B1/ko not_active IP Right Cessation
- 1999-05-28 US US09/322,297 patent/US6395734B1/en not_active Expired - Lifetime
- 1999-05-28 CA CA2314156A patent/CA2314156C/en not_active Expired - Fee Related
- 1999-05-28 TR TR2000/03514T patent/TR200003514T2/xx unknown
- 1999-05-28 CO CO99033314A patent/CO5031249A1/es unknown
- 1999-05-28 DK DK08165009.5T patent/DK2020408T3/da active
- 1999-05-28 EP EP08165009.5A patent/EP2020408B1/en not_active Expired - Lifetime
- 1999-05-28 ES ES08165009T patent/ES2429573T3/es not_active Expired - Lifetime
- 1999-05-28 NZ NZ508815A patent/NZ508815A/en not_active IP Right Cessation
- 1999-05-28 AU AU44102/99A patent/AU759226B2/en not_active Ceased
- 1999-05-28 CN CNB998092487A patent/CN1250526C/zh not_active Expired - Fee Related
- 1999-05-28 EP EP99927120A patent/EP1082305A4/en not_active Ceased
- 1999-05-28 WO PCT/US1999/012069 patent/WO1999061422A1/en active Search and Examination
- 1999-05-28 SK SK1806-2000A patent/SK287132B6/sk not_active IP Right Cessation
- 1999-05-28 AR ARP990102526A patent/AR018408A1/es active IP Right Grant
- 1999-05-28 BR BR9910792-9A patent/BR9910792A/pt not_active Application Discontinuation
- 1999-05-28 PT PT81650095T patent/PT2020408E/pt unknown
- 1999-05-28 EA EA200001258A patent/EA005032B1/ru not_active IP Right Cessation
- 1999-05-28 PL PL99344477A patent/PL344477A1/xx not_active Application Discontinuation
- 1999-05-29 TW TW088108925A patent/TWI229073B/zh not_active IP Right Cessation
2000
- 2000-11-22 NO NO20005916A patent/NO318083B1/no not_active IP Right Cessation
2002
- 2002-02-25 US US10/081,147 patent/US7119090B2/en not_active Expired - Fee Related
2009
- 2009-06-30 HK HK09105836.8A patent/HK1126770A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU759226B2 (en)	2003-04-10
EA005032B1 (ru)	2004-10-28
IL139934A (en)	2007-10-31
CA2314156A1 (en)	1999-12-02
CO5031249A1 (es)	2001-04-27
NO20005916D0 (no)	2000-11-22
EP2020408B1 (en)	2013-06-26
HUP0103617A2 (hu)	2002-02-28
HK1126770A1 (en)	2009-09-11
NO20005916L (no)	2001-01-29
PL344477A1 (en)	2001-11-05
EP1082305A4 (en)	2001-09-26
AU4410299A (en)	1999-12-13
WO1999061422A1 (en)	1999-12-02
US6395734B1 (en)	2002-05-28
KR20010083039A (ko)	2001-08-31
CN1250526C (zh)	2006-04-12
JP4528440B2 (ja)	2010-08-18
PT2020408E (pt)	2013-09-13
EP2020408A1 (en)	2009-02-04
ES2429573T3 (es)	2013-11-15
NZ508815A (en)	2005-02-25
TR200003514T2 (tr)	2002-05-21
IL139934A0 (en)	2002-02-10
JP2002516310A (ja)	2002-06-04
BR9910792A (pt)	2002-01-29
CA2314156C (en)	2010-05-25
EP1082305A1 (en)	2001-03-14
EA200001258A1 (ru)	2001-08-27
US7119090B2 (en)	2006-10-10
AR018408A1 (es)	2001-11-14
KR100743287B1 (ko)	2007-07-26
US20030105151A1 (en)	2003-06-05
TWI229073B (en)	2005-03-11
SK18062000A3 (sk)	2001-06-11
DK2020408T3 (da)	2013-09-30
SK287132B6 (sk)	2009-12-07
CN1311775A (zh)	2001-09-05

Legal Events

Date	Code	Title	Description
2016-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO318083B1 (no)	2005-01-31	Pyrrolsubstituert 2-indolinon protein kinase inhibitorer
US6573293B2 (en)	2003-06-03	Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2000008202A2 (en)	2000-02-17	3-methylidenyl-2-indolinone modulators of protein kinase
NO326604B1 (no)	2009-01-19	3-(4-amidopyrrol-2-ylmetliden)-2-indolinonderivater, fremstilling av slike, farmasoytiske preparater inneholdende slike, metode for a modulere den katalytiske aktiviteten til en proteinkinase in vitro med slike forbindelser samt anvendelse av slike forbindelser for fremstilling av medikament for behandling av sykdommer hos pattedyr
AU2001239770A1 (en)	2001-11-08	Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2002511852A (ja)	2002-04-16	蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
EP1117397A1 (en)	2001-07-25	Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
CA2368041A1 (en)	2000-09-28	Indolinone compounds as kinase inhibitors
WO2002002551A1 (en)	2002-01-10	4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US7214700B2 (en)	2007-05-08	(2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors
US6531502B1 (en)	2003-03-11	3-Methylidenyl-2-indolinone modulators of protein kinase
MXPA00011770A (en)	2002-07-25	Pyrrole substituted 2-indolinone protein kinase inhibitors
CZ20004412A3 (cs)	2001-05-16	Pyrrolem substituované 2-indoIinony jako inhibitory proteinkinázy